WO1996013262A1 - Muscarine antagonists - Google Patents
Muscarine antagonists Download PDFInfo
- Publication number
- WO1996013262A1 WO1996013262A1 PCT/US1995/013710 US9513710W WO9613262A1 WO 1996013262 A1 WO1996013262 A1 WO 1996013262A1 US 9513710 W US9513710 W US 9513710W WO 9613262 A1 WO9613262 A1 WO 9613262A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- piperidin
- dihydro
- benzimidazol
- pyrimidinecarbonyl
- ethyl
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title description 8
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 72
- 150000001875 compounds Chemical class 0.000 claims abstract description 51
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 187
- 239000000203 mixture Substances 0.000 claims description 87
- -1 OEt Chemical group 0.000 claims description 31
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- GDLQVRVYYNREOI-UHFFFAOYSA-N 3-[1-(4-oxocyclohexyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(=O)CCC1N1CCC(N2C(NC3=CC=CC=C32)=O)CC1 GDLQVRVYYNREOI-UHFFFAOYSA-N 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- YFZAQAVOYLEPPC-UHFFFAOYSA-N 6-ethyl-3-[1-[1-(pyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC(CC)=CC=C2N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CN=CN=C1 YFZAQAVOYLEPPC-UHFFFAOYSA-N 0.000 claims description 6
- 201000009487 Amblyopia Diseases 0.000 claims description 6
- PVYNFDRPGQVVAT-UAPYVXQJSA-N O=c1[nH]c2ccccc2n1C1CCN(CC1)[C@H]1CC[C@@H](CC1)Nc1cccnc1 Chemical compound O=c1[nH]c2ccccc2n1C1CCN(CC1)[C@H]1CC[C@@H](CC1)Nc1cccnc1 PVYNFDRPGQVVAT-UAPYVXQJSA-N 0.000 claims description 6
- 230000002159 abnormal effect Effects 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- FKJIVUDILTWFMU-UHFFFAOYSA-N 3-[1-[1-(6-chloropyrazine-2-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound ClC1=CN=CC(C(=O)N2CCC(CC2)N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)=N1 FKJIVUDILTWFMU-UHFFFAOYSA-N 0.000 claims description 5
- AGZOJYPLNHPRCY-UHFFFAOYSA-N 3-[1-[1-(pyrazine-2-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C1=CN=CC=N1 AGZOJYPLNHPRCY-UHFFFAOYSA-N 0.000 claims description 5
- XMGRQOILRXYVFI-UHFFFAOYSA-N 3-[1-[1-(pyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C1=CN=CN=C1 XMGRQOILRXYVFI-UHFFFAOYSA-N 0.000 claims description 5
- XOVBAPLFYJUGIJ-UHFFFAOYSA-N 6-methoxy-3-[1-[1-(pyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC(OC)=CC=C2N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CN=CN=C1 XOVBAPLFYJUGIJ-UHFFFAOYSA-N 0.000 claims description 5
- AHUNRBJNXREORM-UHFFFAOYSA-N 6-methyl-3-[1-[1-(pyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC(C)=CC=C2N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CN=CN=C1 AHUNRBJNXREORM-UHFFFAOYSA-N 0.000 claims description 5
- TYKIUJHABZCOET-IYARVYRRSA-N C1CN([C@@H]2CC[C@H](CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C1=CN=CN=C1 Chemical compound C1CN([C@@H]2CC[C@H](CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C1=CN=CN=C1 TYKIUJHABZCOET-IYARVYRRSA-N 0.000 claims description 5
- QLYMXWCWASMEMO-CTYIDZIISA-N C1C[C@@H](O)CC[C@@H]1N1CCC(N2C(NC3=CC=CC=C32)=O)CC1 Chemical compound C1C[C@@H](O)CC[C@@H]1N1CCC(N2C(NC3=CC=CC=C32)=O)CC1 QLYMXWCWASMEMO-CTYIDZIISA-N 0.000 claims description 5
- QYDXGGUWRWLCQM-UXZPVRCRSA-N N1=CN=CC(=C1)C([C@H]1CC[C@H](CC1)N1CCC(CC1)N1C(NC2=C1C=CC=C2)=O)O Chemical compound N1=CN=CC(=C1)C([C@H]1CC[C@H](CC1)N1CCC(CC1)N1C(NC2=C1C=CC=C2)=O)O QYDXGGUWRWLCQM-UXZPVRCRSA-N 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 239000002831 pharmacologic agent Substances 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- OKODTVDHDGOYCK-UHFFFAOYSA-N 3-[1-[1-(1-pyrazin-2-ylethyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(C)C1=CN=CC=N1 OKODTVDHDGOYCK-UHFFFAOYSA-N 0.000 claims description 4
- IHWDWCYRCMYVSP-UHFFFAOYSA-N 3-[1-[1-(1h-imidazol-5-ylmethyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C(CC1)CCN1C(CC1)CCN1CC1=CNC=N1 IHWDWCYRCMYVSP-UHFFFAOYSA-N 0.000 claims description 4
- JOOBUZBASNSGGK-UHFFFAOYSA-N 3-[1-[1-(2-aminopyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=NC(N)=NC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 JOOBUZBASNSGGK-UHFFFAOYSA-N 0.000 claims description 4
- SWINSGNUAVKOSS-UHFFFAOYSA-N 3-[1-[1-(2-phenylpyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C(C=N1)=CN=C1C1=CC=CC=C1 SWINSGNUAVKOSS-UHFFFAOYSA-N 0.000 claims description 4
- GUWNSXWOJKXCJJ-UHFFFAOYSA-N 3-[1-[1-(2-pyrimidin-5-ylpropan-2-yl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(C)(C)C1=CN=CN=C1 GUWNSXWOJKXCJJ-UHFFFAOYSA-N 0.000 claims description 4
- CVOAXYNAORNVSB-UHFFFAOYSA-N 3-[1-[1-(4-aminopyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound NC1=NC=NC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 CVOAXYNAORNVSB-UHFFFAOYSA-N 0.000 claims description 4
- CULABSQRPXAUMR-UHFFFAOYSA-N 3-[1-[1-(6-aminopyrazine-2-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound NC1=CN=CC(C(=O)N2CCC(CC2)N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)=N1 CULABSQRPXAUMR-UHFFFAOYSA-N 0.000 claims description 4
- XMCGUOBOFLRQCC-UHFFFAOYSA-N 3-[1-[1-(6-phenylmethoxypyrazine-2-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C(N=1)=CN=CC=1OCC1=CC=CC=C1 XMCGUOBOFLRQCC-UHFFFAOYSA-N 0.000 claims description 4
- FTDIHBNIVUOKJC-UHFFFAOYSA-N 3-[1-[1-(pyrimidin-5-ylmethyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C(CC1)CCN1C(CC1)CCN1CC1=CN=CN=C1 FTDIHBNIVUOKJC-UHFFFAOYSA-N 0.000 claims description 4
- DCRAVRWUIWFLIN-UHFFFAOYSA-N 6-fluoro-3-[1-[1-(pyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC(F)=CC=C2N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CN=CN=C1 DCRAVRWUIWFLIN-UHFFFAOYSA-N 0.000 claims description 4
- KZSNYYPEVMAVPJ-UHFFFAOYSA-N 6-methyl-3-[1-[1-(2-pyridin-3-ylpropan-2-yl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC(C)=CC=C2N1C(CC1)CCN1C(CC1)CCN1C(C)(C)C1=CC=CN=C1 KZSNYYPEVMAVPJ-UHFFFAOYSA-N 0.000 claims description 4
- NFNVQTYCONZOBH-UHFFFAOYSA-N 6-methyl-3-[1-[1-(2-pyrimidin-5-ylpropan-2-yl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC(C)=CC=C2N1C(CC1)CCN1C(CC1)CCN1C(C)(C)C1=CN=CN=C1 NFNVQTYCONZOBH-UHFFFAOYSA-N 0.000 claims description 4
- MOQHKFXXEASNDP-UHFFFAOYSA-N 6-methyl-3-[1-[1-(pyridine-3-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC(C)=CC=C2N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CC=CN=C1 MOQHKFXXEASNDP-UHFFFAOYSA-N 0.000 claims description 4
- GGOILMRMJFVHKP-WGSAOQKQSA-N N([C@@H]1CC[C@H](CC1)N1CCC(CC1)N1C(NC2=CC=CC=C21)=O)C(=O)C1=CC=CN=C1 Chemical compound N([C@@H]1CC[C@H](CC1)N1CCC(CC1)N1C(NC2=CC=CC=C21)=O)C(=O)C1=CC=CN=C1 GGOILMRMJFVHKP-WGSAOQKQSA-N 0.000 claims description 4
- LFXLEBXHDDQIRW-MXVIHJGJSA-N N1=CC(=CC=C1)CN1CCN(CC1)[C@@H]1CC[C@H](CC1)N1C(NC2=C1C=CC=C2)=O Chemical compound N1=CC(=CC=C1)CN1CCN(CC1)[C@@H]1CC[C@H](CC1)N1C(NC2=C1C=CC=C2)=O LFXLEBXHDDQIRW-MXVIHJGJSA-N 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- RIDDKZSVOAGNPC-UHFFFAOYSA-N 3-[1-[1-(1-pyrimidin-5-ylethyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(C)C1=CN=CN=C1 RIDDKZSVOAGNPC-UHFFFAOYSA-N 0.000 claims description 3
- GOZNIVVNELMULM-UHFFFAOYSA-N 3-[1-[1-(1h-imidazole-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C1=CNC=N1 GOZNIVVNELMULM-UHFFFAOYSA-N 0.000 claims description 3
- KKNQUTCTFPBRST-UHFFFAOYSA-N 3-[1-[1-(2-pyridin-3-yloxyacetyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)COC1=CC=CN=C1 KKNQUTCTFPBRST-UHFFFAOYSA-N 0.000 claims description 3
- WJOQTVXKYUQYFZ-UHFFFAOYSA-N 3-[1-[1-(3-aminopyrazine-2-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound NC1=NC=CN=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 WJOQTVXKYUQYFZ-UHFFFAOYSA-N 0.000 claims description 3
- XHUIIUJAFBIVFT-UHFFFAOYSA-N 3-[1-[1-(6-methoxypyrazine-2-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound COC1=CN=CC(C(=O)N2CCC(CC2)N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)=N1 XHUIIUJAFBIVFT-UHFFFAOYSA-N 0.000 claims description 3
- KLERSGPWHLWRII-UHFFFAOYSA-N 3-[1-[1-(pyrazin-2-ylmethyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C(CC1)CCN1C(CC1)CCN1CC1=CN=CC=N1 KLERSGPWHLWRII-UHFFFAOYSA-N 0.000 claims description 3
- DFQOQDHQPXPRKG-UHFFFAOYSA-N 4-[4-(2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]-n-(pyridin-3-ylmethyl)piperidine-1-carboxamide Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)NCC1=CC=CN=C1 DFQOQDHQPXPRKG-UHFFFAOYSA-N 0.000 claims description 3
- FQVGYVIHMARJKG-UHFFFAOYSA-N 6-chloro-3-[1-[1-(2-pyrimidin-5-ylpropan-2-yl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC(Cl)=CC=C32)=O)CCN1C(C)(C)C1=CN=CN=C1 FQVGYVIHMARJKG-UHFFFAOYSA-N 0.000 claims description 3
- MKEHBZDVJASDDP-UHFFFAOYSA-N 6-chloro-3-[1-[1-(pyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC(Cl)=CC=C2N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CN=CN=C1 MKEHBZDVJASDDP-UHFFFAOYSA-N 0.000 claims description 3
- FNMIVZINAUSTRZ-UHFFFAOYSA-N 6-methyl-3-[1-[1-(1-pyrazin-2-ylethyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC(C)=CC=C32)=O)CCN1C(C)C1=CN=CC=N1 FNMIVZINAUSTRZ-UHFFFAOYSA-N 0.000 claims description 3
- GGOILMRMJFVHKP-KDURUIRLSA-N N([C@@H]1CC[C@@H](CC1)N1CCC(CC1)N1C(NC2=CC=CC=C21)=O)C(=O)C1=CC=CN=C1 Chemical compound N([C@@H]1CC[C@@H](CC1)N1CCC(CC1)N1C(NC2=CC=CC=C21)=O)C(=O)C1=CC=CN=C1 GGOILMRMJFVHKP-KDURUIRLSA-N 0.000 claims description 3
- QCLFTBSCICTIAI-SAABIXHNSA-N O=C([C@H]1CC[C@@H](CC1)N1CCC(CC1)n1c2ccccc2[nH]c1=O)c1cncnc1 Chemical compound O=C([C@H]1CC[C@@H](CC1)N1CCC(CC1)n1c2ccccc2[nH]c1=O)c1cncnc1 QCLFTBSCICTIAI-SAABIXHNSA-N 0.000 claims description 3
- CLFLUUQJALEIJM-SAABIXHNSA-N O=c1[nH]c2ccccc2n1C1CCN(CC1)[C@H]1CC[C@@H](CC1)Nc1cncnc1 Chemical compound O=c1[nH]c2ccccc2n1C1CCN(CC1)[C@H]1CC[C@@H](CC1)Nc1cncnc1 CLFLUUQJALEIJM-SAABIXHNSA-N 0.000 claims description 3
- QYDXGGUWRWLCQM-MYKGNVCDSA-N OC([C@H]1CC[C@@H](CC1)N1CCC(CC1)n1c2ccccc2[nH]c1=O)c1cncnc1 Chemical compound OC([C@H]1CC[C@@H](CC1)N1CCC(CC1)n1c2ccccc2[nH]c1=O)c1cncnc1 QYDXGGUWRWLCQM-MYKGNVCDSA-N 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 230000018109 developmental process Effects 0.000 claims description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 3
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- GQHGMIQNZHYPGS-UHFFFAOYSA-N 3-[1-(1-pyridin-3-ylsulfonylpiperidin-4-yl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C(CC1)CCN1C(CC1)CCN1S(=O)(=O)C1=CC=CN=C1 GQHGMIQNZHYPGS-UHFFFAOYSA-N 0.000 claims description 2
- QMEGSQPNZGZDEZ-UHFFFAOYSA-N 3-[1-[1-(1,2-oxazol-5-yl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C(CC1)CCN1C(CC1)CCN1C1=CC=NO1 QMEGSQPNZGZDEZ-UHFFFAOYSA-N 0.000 claims description 2
- HMIXLACVUMIATC-UHFFFAOYSA-N 3-[1-[1-(2,4,6-trichlorobenzoyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound ClC1=CC(Cl)=CC(Cl)=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 HMIXLACVUMIATC-UHFFFAOYSA-N 0.000 claims description 2
- DWMXRDZAHFVEDK-UHFFFAOYSA-N 3-[1-[1-(2-methoxybenzoyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound COC1=CC=CC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 DWMXRDZAHFVEDK-UHFFFAOYSA-N 0.000 claims description 2
- SYPXHOBOSRAMFK-UHFFFAOYSA-N 3-[1-[1-(2-methylpyridine-3-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound CC1=NC=CC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 SYPXHOBOSRAMFK-UHFFFAOYSA-N 0.000 claims description 2
- QAMJXAQQHMXXEH-UHFFFAOYSA-N 3-[1-[1-(2-methylpyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=NC(C)=NC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 QAMJXAQQHMXXEH-UHFFFAOYSA-N 0.000 claims description 2
- IMXJVSQPDMDREH-UHFFFAOYSA-N 3-[1-[1-(2-nitrobenzoyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound [O-][N+](=O)C1=CC=CC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 IMXJVSQPDMDREH-UHFFFAOYSA-N 0.000 claims description 2
- FVBOEOLLZFVFJQ-UHFFFAOYSA-N 3-[1-[1-(2-phenylbenzoyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C1=CC=CC=C1C1=CC=CC=C1 FVBOEOLLZFVFJQ-UHFFFAOYSA-N 0.000 claims description 2
- MOOLIABGPOMOSS-UHFFFAOYSA-N 3-[1-[1-(2-pyridin-3-ylacetyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)CC1=CC=CN=C1 MOOLIABGPOMOSS-UHFFFAOYSA-N 0.000 claims description 2
- XSJQDCKYCKRKLE-UHFFFAOYSA-N 3-[1-[1-(2-pyridin-4-ylethanethioyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C(CC1)CCN1C(CC1)CCN1C(=S)CC1=CC=NC=C1 XSJQDCKYCKRKLE-UHFFFAOYSA-N 0.000 claims description 2
- YEGGLQYVGYHYIW-UHFFFAOYSA-N 3-[1-[1-(3,4-dichlorobenzoyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=C(Cl)C(Cl)=CC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 YEGGLQYVGYHYIW-UHFFFAOYSA-N 0.000 claims description 2
- OTWUZCRMQLNDCF-UHFFFAOYSA-N 3-[1-[1-(3,4-dimethoxybenzoyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 OTWUZCRMQLNDCF-UHFFFAOYSA-N 0.000 claims description 2
- VHBHBHJVEPQAJM-UHFFFAOYSA-N 3-[1-[1-(3,5-dimethyl-1,2-oxazol-4-yl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound CC1=NOC(C)=C1N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 VHBHBHJVEPQAJM-UHFFFAOYSA-N 0.000 claims description 2
- ACSYYPYLMPTEON-UHFFFAOYSA-N 3-[1-[1-(3-chloro-1-benzothiophene-2-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=C(Cl)C2=CC=CC=C2S1 ACSYYPYLMPTEON-UHFFFAOYSA-N 0.000 claims description 2
- MXLXEAZGKCGYTG-UHFFFAOYSA-N 3-[1-[1-(3-pyridin-3-ylprop-2-enoyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C=CC1=CC=CN=C1 MXLXEAZGKCGYTG-UHFFFAOYSA-N 0.000 claims description 2
- XKIYZENNQFCBEC-UHFFFAOYSA-N 3-[1-[1-(4-acetylbenzoyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=CC(C(=O)C)=CC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 XKIYZENNQFCBEC-UHFFFAOYSA-N 0.000 claims description 2
- GFPUSFJGFPBFFT-UHFFFAOYSA-N 3-[1-[1-(4-amino-5-chloro-2-methoxybenzoyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 GFPUSFJGFPBFFT-UHFFFAOYSA-N 0.000 claims description 2
- LQXNIANUHKKKJJ-UHFFFAOYSA-N 3-[1-[1-(4-bromobenzoyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=CC(Br)=CC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 LQXNIANUHKKKJJ-UHFFFAOYSA-N 0.000 claims description 2
- CMBRMJYAUNOXAE-UHFFFAOYSA-N 3-[1-[1-(4-fluorobenzoyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=CC(F)=CC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 CMBRMJYAUNOXAE-UHFFFAOYSA-N 0.000 claims description 2
- TYTULSTZPAUDAT-UHFFFAOYSA-N 3-[1-[1-(4-iodobenzoyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=CC(I)=CC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 TYTULSTZPAUDAT-UHFFFAOYSA-N 0.000 claims description 2
- SJEPDQQKFLVUJP-UHFFFAOYSA-N 3-[1-[1-(4-methoxybenzoyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=CC(OC)=CC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 SJEPDQQKFLVUJP-UHFFFAOYSA-N 0.000 claims description 2
- OZFXPSNYVVXAEX-UHFFFAOYSA-N 3-[1-[1-(5-methyl-3,4-dihydropyrazol-2-yl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(C)=NN1N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 OZFXPSNYVVXAEX-UHFFFAOYSA-N 0.000 claims description 2
- PZWNDWGSWBHQKA-UHFFFAOYSA-N 3-[1-[1-(5-nitropyridine-2-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound N1=CC([N+](=O)[O-])=CC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 PZWNDWGSWBHQKA-UHFFFAOYSA-N 0.000 claims description 2
- GHTYAHWHMUUOSS-UHFFFAOYSA-N 3-[1-[1-(5-phenylpyridine-3-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C(C=1)=CN=CC=1C1=CC=CC=C1 GHTYAHWHMUUOSS-UHFFFAOYSA-N 0.000 claims description 2
- XSIRQORHQFDJTO-UHFFFAOYSA-N 3-[1-[1-(6-aminopyridine-3-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=NC(N)=CC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 XSIRQORHQFDJTO-UHFFFAOYSA-N 0.000 claims description 2
- FBMYQCIKEZBDRW-UHFFFAOYSA-N 3-[1-[1-(6-methylpyridine-3-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=NC(C)=CC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 FBMYQCIKEZBDRW-UHFFFAOYSA-N 0.000 claims description 2
- XNHKVCPJWVWNOB-UHFFFAOYSA-N 3-[1-[1-(6-nitropyridine-3-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=NC([N+](=O)[O-])=CC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 XNHKVCPJWVWNOB-UHFFFAOYSA-N 0.000 claims description 2
- RPQQRIFWMODTMW-UHFFFAOYSA-N 3-[1-[1-(quinoline-6-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound N1=CC=CC2=CC(C(N3CCC(CC3)N3CCC(CC3)N3C(NC4=CC=CC=C43)=O)=O)=CC=C21 RPQQRIFWMODTMW-UHFFFAOYSA-N 0.000 claims description 2
- ABYSXAOTPRSGOU-OAQYLSRUSA-N 3-[1-[1-[(2r)-2-amino-3-pyridin-3-ylpropanoyl]piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C([C@@H](N)C(=O)N1CCC(CC1)N1CCC(CC1)N1C(NC2=CC=CC=C21)=O)C1=CC=CN=C1 ABYSXAOTPRSGOU-OAQYLSRUSA-N 0.000 claims description 2
- KERDJVDDDCPMJH-UHFFFAOYSA-N 3-[1-[1-[(4-nitrophenyl)methyl]piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1CN1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 KERDJVDDDCPMJH-UHFFFAOYSA-N 0.000 claims description 2
- UCPQQRDOAATGIQ-UHFFFAOYSA-N 3-[1-[1-[4-(dimethylamino)benzoyl]piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=CC(N(C)C)=CC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 UCPQQRDOAATGIQ-UHFFFAOYSA-N 0.000 claims description 2
- GLKROZLJDRVUNN-UHFFFAOYSA-N 4-[4-[4-(2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]piperidine-1-carbonyl]benzonitrile Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C1=CC=C(C#N)C=C1 GLKROZLJDRVUNN-UHFFFAOYSA-N 0.000 claims description 2
- BXVFLUYBDNPXBQ-UHFFFAOYSA-N 5,6-dimethyl-3-[1-[1-(pyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=2C=C(C)C(C)=CC=2NC(=O)N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CN=CN=C1 BXVFLUYBDNPXBQ-UHFFFAOYSA-N 0.000 claims description 2
- UYPAVSXQGUNNBF-UHFFFAOYSA-N 5-fluoro-3-[1-[1-(pyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC(F)=CC=C2NC(=O)N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CN=CN=C1 UYPAVSXQGUNNBF-UHFFFAOYSA-N 0.000 claims description 2
- QSGSTNJRLLXNBG-UHFFFAOYSA-N 6,7-dimethyl-3-[1-[1-(pyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=C(C)C(C)=CC=C2N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CN=CN=C1 QSGSTNJRLLXNBG-UHFFFAOYSA-N 0.000 claims description 2
- SYHNIIMTONBLTO-UHFFFAOYSA-N 6-(1-hydroxyethyl)-3-[1-[1-(pyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC(C(O)C)=CC=C2N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CN=CN=C1 SYHNIIMTONBLTO-UHFFFAOYSA-N 0.000 claims description 2
- IIYDWRNNUKYAKL-UHFFFAOYSA-N 6-(2-hydroxyethoxy)-3-[1-[1-(pyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC(OCCO)=CC=C2N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CN=CN=C1 IIYDWRNNUKYAKL-UHFFFAOYSA-N 0.000 claims description 2
- IJWPSBZWKRHASD-UHFFFAOYSA-N 6-butyl-3-[1-[1-(pyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC(CCCC)=CC=C2N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CN=CN=C1 IJWPSBZWKRHASD-UHFFFAOYSA-N 0.000 claims description 2
- CVNWEQUBYIGWBJ-UHFFFAOYSA-N 6-chloro-3-[1-[1-(1-pyrazin-2-ylethyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC(Cl)=CC=C32)=O)CCN1C(C)C1=CN=CC=N1 CVNWEQUBYIGWBJ-UHFFFAOYSA-N 0.000 claims description 2
- VIQZDXMHJQVQHB-UHFFFAOYSA-N 6-ethoxy-3-[1-[1-(pyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC(OCC)=CC=C2N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CN=CN=C1 VIQZDXMHJQVQHB-UHFFFAOYSA-N 0.000 claims description 2
- GTROCUBUILYKCU-UHFFFAOYSA-N 6-hydroxy-3-[1-[1-(pyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC(O)=CC=C2N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CN=CN=C1 GTROCUBUILYKCU-UHFFFAOYSA-N 0.000 claims description 2
- HAZXIEKRRJMSIN-UHFFFAOYSA-N 6-propan-2-yl-3-[1-[1-(pyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC(C(C)C)=CC=C2N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CN=CN=C1 HAZXIEKRRJMSIN-UHFFFAOYSA-N 0.000 claims description 2
- CUEFOZJDUDTDNU-UHFFFAOYSA-N 6-propyl-3-[1-[1-(pyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC(CCC)=CC=C2N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CN=CN=C1 CUEFOZJDUDTDNU-UHFFFAOYSA-N 0.000 claims description 2
- MOVXSHYLHRKSDQ-UHFFFAOYSA-N 7-ethyl-3-[1-[1-(pyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC=2C(CC)=CC=CC=2N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CN=CN=C1 MOVXSHYLHRKSDQ-UHFFFAOYSA-N 0.000 claims description 2
- TUXHFSWDJWZVFX-UHFFFAOYSA-N 7-fluoro-3-[1-[1-(pyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC=2C(F)=CC=CC=2N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CN=CN=C1 TUXHFSWDJWZVFX-UHFFFAOYSA-N 0.000 claims description 2
- UITOKZGSRWCMSK-UHFFFAOYSA-N 7-methyl-3-[1-[1-(pyridine-3-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC=2C(C)=CC=CC=2N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CC=CN=C1 UITOKZGSRWCMSK-UHFFFAOYSA-N 0.000 claims description 2
- PFYSSUBUWGDANY-UHFFFAOYSA-N 7-methyl-3-[1-[1-(pyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC=2C(C)=CC=CC=2N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CN=CN=C1 PFYSSUBUWGDANY-UHFFFAOYSA-N 0.000 claims description 2
- DVYRWKDHZXKPRK-WKILWMFISA-N C(C)OC(=O)[C@@H]1CC[C@H](CC1)N1CCC(CC1)N1C(NC2=C1C=CC=C2)=O Chemical compound C(C)OC(=O)[C@@H]1CC[C@H](CC1)N1CCC(CC1)N1C(NC2=C1C=CC=C2)=O DVYRWKDHZXKPRK-WKILWMFISA-N 0.000 claims description 2
- CLJNEHXJFILGRL-IYARVYRRSA-N C1(C=2C(C(N1[C@@H]1CC[C@H](CC1)N1CCC(CC1)N1C(NC3=C1C=CC=C3)=O)=O)=CC=CC=2)=O Chemical compound C1(C=2C(C(N1[C@@H]1CC[C@H](CC1)N1CCC(CC1)N1C(NC3=C1C=CC=C3)=O)=O)=CC=CC=2)=O CLJNEHXJFILGRL-IYARVYRRSA-N 0.000 claims description 2
- UGWKLRLGNLXPDY-KESTWPANSA-N C1=CC([N+](=O)[O-])=CC=C1C(=O)N[C@@H]1CC[C@@H](CN2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)N[C@@H]1CC[C@@H](CN2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 UGWKLRLGNLXPDY-KESTWPANSA-N 0.000 claims description 2
- ZXWVHKDEEAMLKX-KESTWPANSA-N C1CC(N[C@@H]2CC[C@H](CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C1=CC=CN=C1 Chemical compound C1CC(N[C@@H]2CC[C@H](CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C1=CC=CN=C1 ZXWVHKDEEAMLKX-KESTWPANSA-N 0.000 claims description 2
- HIMMASMIUSKBTC-WGSAOQKQSA-N C1CN([C@@H]2CC[C@H](CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C1=CC=CN=C1 Chemical compound C1CN([C@@H]2CC[C@H](CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C1=CC=CN=C1 HIMMASMIUSKBTC-WGSAOQKQSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- LNPWWTMDONWAEB-SHTZXODSSA-N OC[C@@H]1CC[C@H](CC1)N1CCC(CC1)N1C(NC2=C1C=CC=C2)=O Chemical compound OC[C@@H]1CC[C@H](CC1)N1CCC(CC1)N1C(NC2=C1C=CC=C2)=O LNPWWTMDONWAEB-SHTZXODSSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- GSQDUALOBREVCB-UHFFFAOYSA-N benzyl 4-[4-(2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]piperidine-1-carboxylate Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)OCC1=CC=CC=C1 GSQDUALOBREVCB-UHFFFAOYSA-N 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
- VSKPUERCNVNEKD-UHFFFAOYSA-N methyl 4-[4-[4-(2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]piperidine-1-carbonyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 VSKPUERCNVNEKD-UHFFFAOYSA-N 0.000 claims description 2
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims description 2
- 125000005499 phosphonyl group Chemical group 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- VTAUQOFJPHRZJY-UHFFFAOYSA-N pyridin-3-ylmethyl 4-[4-(2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]piperidine-1-carboxylate Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)OCC1=CC=CN=C1 VTAUQOFJPHRZJY-UHFFFAOYSA-N 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- YCUFZFBDMDBPEH-RUZDIDTESA-N tert-butyl n-[(2r)-1-oxo-1-[4-[4-(2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]piperidin-1-yl]-3-pyridin-3-ylpropan-2-yl]carbamate Chemical compound C([C@@H](NC(=O)OC(C)(C)C)C(=O)N1CCC(CC1)N1CCC(CC1)N1C(NC2=CC=CC=C21)=O)C1=CC=CN=C1 YCUFZFBDMDBPEH-RUZDIDTESA-N 0.000 claims description 2
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 2
- 210000001110 axial length eye Anatomy 0.000 claims 4
- 230000003551 muscarinic effect Effects 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- YSPTYALVNBVGAP-UHFFFAOYSA-N 3-[1-[1-(3-pyridin-3-ylpropanoyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)CCC1=CC=CN=C1 YSPTYALVNBVGAP-UHFFFAOYSA-N 0.000 claims 1
- LOOBQNVHEBZJKV-UHFFFAOYSA-N 3-[1-[1-(6-morpholin-4-ylpyridine-3-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C(C=N1)=CC=C1N1CCOCC1 LOOBQNVHEBZJKV-UHFFFAOYSA-N 0.000 claims 1
- FOMKCUIKDBIUSL-UHFFFAOYSA-N 3-[1-[1-(pyrimidine-4-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C1=CC=NC=N1 FOMKCUIKDBIUSL-UHFFFAOYSA-N 0.000 claims 1
- GVNREFIURNPOGV-UHFFFAOYSA-N 3-[1-[1-(quinoline-2-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=CC=CC2=NC(C(N3CCC(CC3)N3CCC(CC3)N3C(NC4=CC=CC=C43)=O)=O)=CC=C21 GVNREFIURNPOGV-UHFFFAOYSA-N 0.000 claims 1
- AHGTUOHQQALSBG-WGSAOQKQSA-N C1=CC([N+](=O)[O-])=CC=C1C(=O)N1CCN([C@@H]2CC[C@H](CC2)N2C(NC3=CC=CC=C32)=O)CC1 Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)N1CCN([C@@H]2CC[C@H](CC2)N2C(NC3=CC=CC=C32)=O)CC1 AHGTUOHQQALSBG-WGSAOQKQSA-N 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 230000003455 independent Effects 0.000 claims 1
- 230000004379 myopia Effects 0.000 abstract description 12
- 208000001491 myopia Diseases 0.000 abstract description 12
- YRUIFZZCBJRIMO-UHFFFAOYSA-N 3-(1-piperidin-4-ylpiperidin-4-yl)-1h-benzimidazol-2-one Chemical class O=C1NC2=CC=CC=C2N1C(CC1)CCN1C1CCNCC1 YRUIFZZCBJRIMO-UHFFFAOYSA-N 0.000 abstract description 2
- JKSKZGHSSMWPFF-UHFFFAOYSA-N 3-(4-aminocyclohexyl)-1h-benzimidazol-2-one Chemical class C1CC(N)CCC1N1C(=O)NC2=CC=CC=C21 JKSKZGHSSMWPFF-UHFFFAOYSA-N 0.000 abstract description 2
- 230000001022 anti-muscarinic effect Effects 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 174
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 147
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 136
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 129
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 121
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 114
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 104
- 239000007787 solid Substances 0.000 description 96
- 238000005160 1H NMR spectroscopy Methods 0.000 description 90
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 69
- 238000004458 analytical method Methods 0.000 description 63
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 60
- 150000003839 salts Chemical class 0.000 description 58
- 239000000243 solution Substances 0.000 description 58
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 57
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 57
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 55
- 239000010410 layer Substances 0.000 description 52
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 46
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 45
- 235000019439 ethyl acetate Nutrition 0.000 description 42
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 39
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 36
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
- 239000000284 extract Substances 0.000 description 34
- 239000012044 organic layer Substances 0.000 description 31
- 239000011541 reaction mixture Substances 0.000 description 30
- 239000000741 silica gel Substances 0.000 description 30
- 229910002027 silica gel Inorganic materials 0.000 description 30
- 229920006395 saturated elastomer Polymers 0.000 description 29
- 210000001519 tissue Anatomy 0.000 description 29
- 229960000583 acetic acid Drugs 0.000 description 27
- 238000004587 chromatography analysis Methods 0.000 description 26
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 26
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 26
- 238000001035 drying Methods 0.000 description 24
- 229910000029 sodium carbonate Inorganic materials 0.000 description 22
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 21
- 239000012362 glacial acetic acid Substances 0.000 description 21
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 20
- 238000010992 reflux Methods 0.000 description 20
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 18
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 12
- 239000012043 crude product Substances 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 10
- 229960004484 carbachol Drugs 0.000 description 10
- 210000003205 muscle Anatomy 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 229930003347 Atropine Natural products 0.000 description 8
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 8
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 8
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 8
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 8
- 229960000396 atropine Drugs 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000012230 colorless oil Substances 0.000 description 8
- 238000012746 preparative thin layer chromatography Methods 0.000 description 8
- WUODBFNKRHHMPW-UHFFFAOYSA-N 3-(4-oxocyclohexyl)-1h-benzimidazol-2-one Chemical compound C1CC(=O)CCC1N1C(=O)NC2=CC=CC=C21 WUODBFNKRHHMPW-UHFFFAOYSA-N 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 7
- 239000003149 muscarinic antagonist Substances 0.000 description 7
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 238000001665 trituration Methods 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- BYNBAMHAURJNTR-UHFFFAOYSA-N 3-piperidin-4-yl-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C1CCNCC1 BYNBAMHAURJNTR-UHFFFAOYSA-N 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N butenedioic acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 210000001525 retina Anatomy 0.000 description 6
- PYOBAVFUQVVJKZ-UHFFFAOYSA-N 1-(1-pyrazin-2-ylethyl)piperidin-4-one Chemical compound C=1N=CC=NC=1C(C)N1CCC(=O)CC1 PYOBAVFUQVVJKZ-UHFFFAOYSA-N 0.000 description 5
- 0 CCCC(CC***C)*C(C)=C(N**=O)N=C Chemical compound CCCC(CC***C)*C(C)=C(N**=O)N=C 0.000 description 5
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 5
- 239000005977 Ethylene Substances 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000003889 eye drop Substances 0.000 description 5
- 229940012356 eye drops Drugs 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 210000003405 ileum Anatomy 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 5
- NFKXXURQUMEXDJ-UHFFFAOYSA-N pyrimidine-5-carbonyl chloride Chemical compound ClC(=O)C1=CN=CN=C1 NFKXXURQUMEXDJ-UHFFFAOYSA-N 0.000 description 5
- 238000003653 radioligand binding assay Methods 0.000 description 5
- 229940044551 receptor antagonist Drugs 0.000 description 5
- 239000002464 receptor antagonist Substances 0.000 description 5
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 5
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 239000007836 KH2PO4 Substances 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000005903 acid hydrolysis reaction Methods 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 230000001886 ciliary effect Effects 0.000 description 4
- 150000001860 citric acid derivatives Chemical class 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 210000002837 heart atrium Anatomy 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
- 230000004423 myopia development Effects 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 4
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000012258 stirred mixture Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- GWCPZMRPJBYIFM-RXMQYKEDSA-N (1r)-1-pyrimidin-5-ylethanamine Chemical compound C[C@@H](N)C1=CN=CN=C1 GWCPZMRPJBYIFM-RXMQYKEDSA-N 0.000 description 3
- GWCPZMRPJBYIFM-YFKPBYRVSA-N (1s)-1-pyrimidin-5-ylethanamine Chemical compound C[C@H](N)C1=CN=CN=C1 GWCPZMRPJBYIFM-YFKPBYRVSA-N 0.000 description 3
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 3
- LMQPCACOOKKMHW-UHFFFAOYSA-M 1,1-dimethylpiperidin-1-ium-4-one;iodide Chemical compound [I-].C[N+]1(C)CCC(=O)CC1 LMQPCACOOKKMHW-UHFFFAOYSA-M 0.000 description 3
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 3
- YBUVWNZVLXGWMB-UHFFFAOYSA-N 3-[1-[1-(2-pyridin-3-ylpropan-2-yl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(C)(C)C1=CC=CN=C1 YBUVWNZVLXGWMB-UHFFFAOYSA-N 0.000 description 3
- VVCPOMCVACQHOM-UHFFFAOYSA-N 3-[1-[1-(pyridazine-4-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C1=CC=NN=C1 VVCPOMCVACQHOM-UHFFFAOYSA-N 0.000 description 3
- XVIHWNAPNIKGFL-UHFFFAOYSA-N 3-[1-[1-(pyridine-3-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C1=CC=CN=C1 XVIHWNAPNIKGFL-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- XIWJPPDWLBWIGR-HDJSIYSDSA-N N1([C@H]2CC[C@@H](CC2)N2C3=CC=CC=C3NC2=O)CCNCC1 Chemical compound N1([C@H]2CC[C@@H](CC2)N2C3=CC=CC=C3NC2=O)CCNCC1 XIWJPPDWLBWIGR-HDJSIYSDSA-N 0.000 description 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 230000004329 axial myopia Effects 0.000 description 3
- 230000001713 cholinergic effect Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 229940124570 cycloplegic agent Drugs 0.000 description 3
- 229960001270 d- tartaric acid Drugs 0.000 description 3
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- NJCDAOMVXVONIU-UHFFFAOYSA-N ethyl 2-(4-chloro-2-methylsulfanylpyrimidin-5-yl)acetate Chemical compound CCOC(=O)CC1=CN=C(SC)N=C1Cl NJCDAOMVXVONIU-UHFFFAOYSA-N 0.000 description 3
- GQQQULCEHJQUJT-UHFFFAOYSA-N ethyl 4-aminopiperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(N)CC1 GQQQULCEHJQUJT-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229960004633 pirenzepine Drugs 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001177 vas deferen Anatomy 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- IQVQNBXPYJGNEA-ZCFIWIBFSA-N (1r)-1-pyridin-3-ylethanamine Chemical compound C[C@@H](N)C1=CC=CN=C1 IQVQNBXPYJGNEA-ZCFIWIBFSA-N 0.000 description 2
- VKRKCBWIVLSRBJ-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-8-one Chemical compound C1CC(=O)CCC21OCCO2 VKRKCBWIVLSRBJ-UHFFFAOYSA-N 0.000 description 2
- ZQLHNXGDZDWKBI-UHFFFAOYSA-N 1-(1-pyrimidin-5-ylethyl)piperidin-4-one Chemical compound C=1N=CN=CC=1C(C)N1CCC(=O)CC1 ZQLHNXGDZDWKBI-UHFFFAOYSA-N 0.000 description 2
- PDKIGPTUVAAFGE-UHFFFAOYSA-N 1-(2-pyrimidin-5-ylpropan-2-yl)piperidin-4-one Chemical compound C=1N=CN=CC=1C(C)(C)N1CCC(=O)CC1 PDKIGPTUVAAFGE-UHFFFAOYSA-N 0.000 description 2
- IIGXIHLJMZQHJY-UHFFFAOYSA-N 1-pyrazin-2-ylethanamine Chemical compound CC(N)C1=CN=CC=N1 IIGXIHLJMZQHJY-UHFFFAOYSA-N 0.000 description 2
- LRQUNKQRPBWOQQ-UHFFFAOYSA-N 1-pyrazin-2-ylethanol Chemical compound CC(O)C1=CN=CC=N1 LRQUNKQRPBWOQQ-UHFFFAOYSA-N 0.000 description 2
- QMDUEBURHKSKDG-UHFFFAOYSA-N 1-pyridin-3-ylethanol Chemical compound CC(O)C1=CC=CN=C1 QMDUEBURHKSKDG-UHFFFAOYSA-N 0.000 description 2
- DZWXTJDQFCUBPG-UHFFFAOYSA-N 2-(1-azidoethyl)pyrazine Chemical compound [N-]=[N+]=NC(C)C1=CN=CC=N1 DZWXTJDQFCUBPG-UHFFFAOYSA-N 0.000 description 2
- GCLLRSFONGULDU-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]pyrimidine-5-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1=NC=C(C(O)=O)C=N1 GCLLRSFONGULDU-UHFFFAOYSA-N 0.000 description 2
- DBZAKQWXICEWNW-UHFFFAOYSA-N 2-acetylpyrazine Chemical compound CC(=O)C1=CN=CC=N1 DBZAKQWXICEWNW-UHFFFAOYSA-N 0.000 description 2
- PQZHAIJWOSIAJT-UHFFFAOYSA-N 2-pyrimidin-5-ylpropan-2-amine Chemical compound CC(C)(N)C1=CN=CN=C1 PQZHAIJWOSIAJT-UHFFFAOYSA-N 0.000 description 2
- RFGGVMSMTOSPBR-ZCFIWIBFSA-N 3-[(1r)-1-azidoethyl]pyridine Chemical compound [N-]=[N+]=N[C@H](C)C1=CC=CN=C1 RFGGVMSMTOSPBR-ZCFIWIBFSA-N 0.000 description 2
- NHFCQLYKADDUPS-UHFFFAOYSA-N 3-[1-[1-(6-azidopyrazine-2-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound [N-]=[N+]=NC1=CN=CC(C(=O)N2CCC(CC2)N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)=N1 NHFCQLYKADDUPS-UHFFFAOYSA-N 0.000 description 2
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
- WGNUNYPERJMVRM-UHFFFAOYSA-N 3-pyridylacetic acid Chemical group OC(=O)CC1=CC=CN=C1 WGNUNYPERJMVRM-UHFFFAOYSA-N 0.000 description 2
- BOGBWQHEGGANDQ-UHFFFAOYSA-N 4-(pyridine-3-carbonylamino)piperidine-1-carboxylic acid Chemical compound C1CN(C(=O)O)CCC1NC(=O)C1=CC=CN=C1 BOGBWQHEGGANDQ-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- CXFZFEJJLNLOTA-UHFFFAOYSA-N 4-[(3-chlorophenyl)carbamoyloxy]but-2-ynyl-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC#CCOC(=O)NC1=CC=CC(Cl)=C1 CXFZFEJJLNLOTA-UHFFFAOYSA-N 0.000 description 2
- QVQJVKCQKVFTPX-UHFFFAOYSA-N 4-[4-(2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]cyclohexane-1-carbaldehyde Chemical class C1CC(C=O)CCC1N1CCC(N2C(NC3=CC=CC=C32)=O)CC1 QVQJVKCQKVFTPX-UHFFFAOYSA-N 0.000 description 2
- SWCPDZUJMKCHMJ-UHFFFAOYSA-N 5-(2-isocyanatopropan-2-yl)pyrimidine Chemical compound O=C=NC(C)(C)C1=CN=CN=C1 SWCPDZUJMKCHMJ-UHFFFAOYSA-N 0.000 description 2
- KGGYMBKTQCLOTE-UHFFFAOYSA-N 6-chloropyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC(Cl)=N1 KGGYMBKTQCLOTE-UHFFFAOYSA-N 0.000 description 2
- AWSJFOUAEDCEGT-UHFFFAOYSA-N 6-methyl-3-piperidin-4-yl-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC(C)=CC=C2N1C1CCNCC1 AWSJFOUAEDCEGT-UHFFFAOYSA-N 0.000 description 2
- INWXUSXDYYNSLM-UHFFFAOYSA-N 6-phenylmethoxypyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC(OCC=2C=CC=CC=2)=N1 INWXUSXDYYNSLM-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- GSEYIZXXHGPJRW-QAQDUYKDSA-N C1CN(C(=O)C(C)(C)C)CCN1[C@@H]1CC[C@@H](N2C(NC3=CC=CC=C32)=O)CC1 Chemical compound C1CN(C(=O)C(C)(C)C)CCN1[C@@H]1CC[C@@H](N2C(NC3=CC=CC=C32)=O)CC1 GSEYIZXXHGPJRW-QAQDUYKDSA-N 0.000 description 2
- YTFAAGJZOKPFNO-JCNLHEQBSA-N C1CN(C(=O)OCC)CCC1N[C@@H]1CC[C@@H](N2C(NC3=CC=CC=C32)=O)CC1 Chemical compound C1CN(C(=O)OCC)CCC1N[C@@H]1CC[C@@H](N2C(NC3=CC=CC=C32)=O)CC1 YTFAAGJZOKPFNO-JCNLHEQBSA-N 0.000 description 2
- 241000252983 Caecum Species 0.000 description 2
- 102000009660 Cholinergic Receptors Human genes 0.000 description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LIPDDQUUGPQGCC-CTYIDZIISA-N N([C@H]1CC[C@@H](CC1)N1C2=CC=CC=C2NC1=O)C1CCNCC1 Chemical compound N([C@H]1CC[C@@H](CC1)N1C2=CC=CC=C2NC1=O)C1CCNCC1 LIPDDQUUGPQGCC-CTYIDZIISA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- KLXKCRQGBLBRJL-UHFFFAOYSA-N OC(CC1)CCC1N(CC1)CCC1N(c(ccc(Cl)c1)c1N1)C1=O Chemical compound OC(CC1)CCC1N(CC1)CCC1N(c(ccc(Cl)c1)c1N1)C1=O KLXKCRQGBLBRJL-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 2
- 239000000634 cycloplegic agent Substances 0.000 description 2
- 230000003500 cycloplegic effect Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- BNFDGIDARAYBRK-UHFFFAOYSA-N ethyl 2-[(2-methylpropan-2-yl)oxycarbonylamino]pyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(NC(=O)OC(C)(C)C)N=C1 BNFDGIDARAYBRK-UHFFFAOYSA-N 0.000 description 2
- WUMAVJLKQPPOHB-UHFFFAOYSA-N ethyl 2-methyl-2-pyrimidin-5-ylpropanoate Chemical compound CCOC(=O)C(C)(C)C1=CN=CN=C1 WUMAVJLKQPPOHB-UHFFFAOYSA-N 0.000 description 2
- JYFYKRSTLSLCFM-UHFFFAOYSA-N ethyl 2-pyrimidin-5-ylacetate Chemical compound CCOC(=O)CC1=CN=CN=C1 JYFYKRSTLSLCFM-UHFFFAOYSA-N 0.000 description 2
- RWIFOOGSCDYPTE-UHFFFAOYSA-N ethyl 4-(4-methyl-2-nitroanilino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=CC=C(C)C=C1[N+]([O-])=O RWIFOOGSCDYPTE-UHFFFAOYSA-N 0.000 description 2
- XMLUIZYWNUBDDQ-UHFFFAOYSA-N ethyl 4-(5-methyl-2-oxo-3h-benzimidazol-1-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1N1C(=O)NC2=CC(C)=CC=C21 XMLUIZYWNUBDDQ-UHFFFAOYSA-N 0.000 description 2
- DVYRWKDHZXKPRK-UHFFFAOYSA-N ethyl 4-[4-(2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]cyclohexane-1-carboxylate Chemical class C1CC(C(=O)OCC)CCC1N1CCC(N2C(NC3=CC=CC=C32)=O)CC1 DVYRWKDHZXKPRK-UHFFFAOYSA-N 0.000 description 2
- HSYNOGRYGMCSNI-UHFFFAOYSA-N ethyl N-pyridin-2-yl-N-(pyridin-3-ylmethoxy)carbamate Chemical compound N1=CC(=CC=C1)CON(C(=O)OCC)C1=NC=CC=C1 HSYNOGRYGMCSNI-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 238000011597 hartley guinea pig Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 229950007593 homonicotinic acid Drugs 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- JEUFIZJHQJXHAU-UHFFFAOYSA-M lithium;2-methyl-2-pyrimidin-5-ylpropanoate Chemical compound [Li+].[O-]C(=O)C(C)(C)C1=CN=CN=C1 JEUFIZJHQJXHAU-UHFFFAOYSA-M 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000472 muscarinic agonist Substances 0.000 description 2
- BSGCAADUBFYIEL-UHFFFAOYSA-N n-piperidin-4-ylpyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC1CCNCC1 BSGCAADUBFYIEL-UHFFFAOYSA-N 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000001722 neurochemical effect Effects 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 238000004305 normal phase HPLC Methods 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- CKIBIGYFKUYQRY-UHFFFAOYSA-N tert-butyl 4-[4-(2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1CCC(N2C(NC3=CC=CC=C32)=O)CC1 CKIBIGYFKUYQRY-UHFFFAOYSA-N 0.000 description 2
- JWOQLBOJFFOKTP-UHFFFAOYSA-N tert-butyl 4-[4-(5-methyl-2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]piperidine-1-carboxylate Chemical compound O=C1NC2=CC(C)=CC=C2N1C(CC1)CCN1C1CCN(C(=O)OC(C)(C)C)CC1 JWOQLBOJFFOKTP-UHFFFAOYSA-N 0.000 description 2
- DQARDWKWPIRJEH-UHFFFAOYSA-N tert-butyl n-(4-hydroxycyclohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCC(O)CC1 DQARDWKWPIRJEH-UHFFFAOYSA-N 0.000 description 2
- WYVFPGFWUKBXPZ-UHFFFAOYSA-N tert-butyl n-(4-oxocyclohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCC(=O)CC1 WYVFPGFWUKBXPZ-UHFFFAOYSA-N 0.000 description 2
- UYIWBSCVYQRGHI-UHFFFAOYSA-N tert-butyl n-[5-[4-[4-(2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]piperidine-1-carbonyl]pyrimidin-2-yl]carbamate Chemical compound C1=NC(NC(=O)OC(C)(C)C)=NC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 UYIWBSCVYQRGHI-UHFFFAOYSA-N 0.000 description 2
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 description 1
- QMDUEBURHKSKDG-ZCFIWIBFSA-N (1r)-1-pyridin-3-ylethanol Chemical compound C[C@@H](O)C1=CC=CN=C1 QMDUEBURHKSKDG-ZCFIWIBFSA-N 0.000 description 1
- IJXJGQCXFSSHNL-MRVPVSSYSA-N (2s)-2-amino-2-phenylethanol Chemical compound OC[C@@H](N)C1=CC=CC=C1 IJXJGQCXFSSHNL-MRVPVSSYSA-N 0.000 description 1
- RXIQKSZSJLADAQ-UHFFFAOYSA-N (4-nitrophenyl) pyridin-3-ylmethyl carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OCC1=CC=CN=C1 RXIQKSZSJLADAQ-UHFFFAOYSA-N 0.000 description 1
- IJXJGQCXFSSHNL-QMMMGPOBSA-N (R)-(-)-2-Phenylglycinol Chemical compound OC[C@H](N)C1=CC=CC=C1 IJXJGQCXFSSHNL-QMMMGPOBSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- YZPAKBGVJIVPEU-UHFFFAOYSA-N 1,2-benzodiazepin-6-one Chemical compound N1=NC=CC=C2C(=O)C=CC=C21 YZPAKBGVJIVPEU-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- RZKKOBGFCAHLCZ-UHFFFAOYSA-N 1,4-dichloro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC=C1Cl RZKKOBGFCAHLCZ-UHFFFAOYSA-N 0.000 description 1
- MXBMKNNPFIPIBM-UHFFFAOYSA-N 1-bromo-4-ethyl-2-nitrobenzene Chemical compound CCC1=CC=C(Br)C([N+]([O-])=O)=C1 MXBMKNNPFIPIBM-UHFFFAOYSA-N 0.000 description 1
- DVXDJQKEEKXJBW-UHFFFAOYSA-N 1-chloro-4-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(F)=CC=C1Cl DVXDJQKEEKXJBW-UHFFFAOYSA-N 0.000 description 1
- HISHUMDTGXICEZ-UHFFFAOYSA-N 1-chloro-4-methoxy-2-nitrobenzene Chemical compound COC1=CC=C(Cl)C([N+]([O-])=O)=C1 HISHUMDTGXICEZ-UHFFFAOYSA-N 0.000 description 1
- NWESJZZPAJGHRZ-UHFFFAOYSA-N 1-chloro-4-methyl-2-nitrobenzene Chemical compound CC1=CC=C(Cl)C([N+]([O-])=O)=C1 NWESJZZPAJGHRZ-UHFFFAOYSA-N 0.000 description 1
- PIDODLRGSKHQDP-UHFFFAOYSA-M 1-ethyl-1-methylpiperidin-1-ium-4-one;iodide Chemical compound [I-].CC[N+]1(C)CCC(=O)CC1 PIDODLRGSKHQDP-UHFFFAOYSA-M 0.000 description 1
- IQVQNBXPYJGNEA-UHFFFAOYSA-N 1-pyridin-3-ylethanamine Chemical compound CC(N)C1=CC=CN=C1 IQVQNBXPYJGNEA-UHFFFAOYSA-N 0.000 description 1
- GWCPZMRPJBYIFM-UHFFFAOYSA-N 1-pyrimidin-5-ylethanamine Chemical compound CC(N)C1=CN=CN=C1 GWCPZMRPJBYIFM-UHFFFAOYSA-N 0.000 description 1
- NKWCGTOZTHZDHB-UHFFFAOYSA-N 1h-imidazol-1-ium-4-carboxylate Chemical compound OC(=O)C1=CNC=N1 NKWCGTOZTHZDHB-UHFFFAOYSA-N 0.000 description 1
- ZQEXIXXJFSQPNA-UHFFFAOYSA-N 1h-imidazole-5-carbaldehyde Chemical group O=CC1=CNC=N1 ZQEXIXXJFSQPNA-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- GVOYKJPMUUJXBS-UHFFFAOYSA-N 2-(aminomethyl)aniline Chemical compound NCC1=CC=CC=C1N GVOYKJPMUUJXBS-UHFFFAOYSA-N 0.000 description 1
- AJKVQEKCUACUMD-UHFFFAOYSA-N 2-Acetylpyridine Chemical compound CC(=O)C1=CC=CC=N1 AJKVQEKCUACUMD-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- NMGIXZFBQPETOK-UHFFFAOYSA-N 2-methylpyrimidine-5-carboxylic acid Chemical compound CC1=NC=C(C(O)=O)C=N1 NMGIXZFBQPETOK-UHFFFAOYSA-N 0.000 description 1
- BOAIYSRFGWBZCF-UHFFFAOYSA-N 2-phenylpyrimidine-5-carboxylic acid Chemical compound N1=CC(C(=O)O)=CN=C1C1=CC=CC=C1 BOAIYSRFGWBZCF-UHFFFAOYSA-N 0.000 description 1
- MBEPWLCDXKKANL-UHFFFAOYSA-N 2-pyridin-3-yloxyacetic acid Chemical compound OC(=O)COC1=CC=CN=C1 MBEPWLCDXKKANL-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- QWIULLWHMVHUMQ-UHFFFAOYSA-N 3-[1-(1-benzoylpiperidin-4-yl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C1=CC=CC=C1 QWIULLWHMVHUMQ-UHFFFAOYSA-N 0.000 description 1
- ZEUZUUSEPCNVFJ-UHFFFAOYSA-N 3-[1-(1-benzylpiperidin-4-yl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C(CC1)CCN1C(CC1)CCN1CC1=CC=CC=C1 ZEUZUUSEPCNVFJ-UHFFFAOYSA-N 0.000 description 1
- CXPYWAJVWAXOFY-UHFFFAOYSA-N 3-[1-[1-(1-benzofuran-2-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=CC=C2OC(C(N3CCC(CC3)N3CCC(CC3)N3C(NC4=CC=CC=C43)=O)=O)=CC2=C1 CXPYWAJVWAXOFY-UHFFFAOYSA-N 0.000 description 1
- IPTWVWQYRBKOCZ-UHFFFAOYSA-N 3-[1-[1-(1-benzothiophene-3-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=CC=C2C(C(N3CCC(CC3)N3CCC(CC3)N3C(NC4=CC=CC=C43)=O)=O)=CSC2=C1 IPTWVWQYRBKOCZ-UHFFFAOYSA-N 0.000 description 1
- BBEIZAIRVOYSDP-UHFFFAOYSA-N 3-[1-[1-(2,3,4,5,6-pentafluorobenzoyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 BBEIZAIRVOYSDP-UHFFFAOYSA-N 0.000 description 1
- NCFYPYOPBLUHMS-UHFFFAOYSA-N 3-[1-[1-(2-aminopyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one;dihydrochloride Chemical compound Cl.Cl.C1=NC(N)=NC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 NCFYPYOPBLUHMS-UHFFFAOYSA-N 0.000 description 1
- LGUPSANZVZEERF-UHFFFAOYSA-N 3-[1-[1-(3,5-dichlorobenzoyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound ClC1=CC(Cl)=CC(C(=O)N2CCC(CC2)N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)=C1 LGUPSANZVZEERF-UHFFFAOYSA-N 0.000 description 1
- RSMYXCSMZQBTLN-UHFFFAOYSA-N 3-[1-[1-(3-nitrobenzoyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound [O-][N+](=O)C1=CC=CC(C(=O)N2CCC(CC2)N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)=C1 RSMYXCSMZQBTLN-UHFFFAOYSA-N 0.000 description 1
- BKOZZQHXWUNDHJ-UHFFFAOYSA-N 3-[1-[1-(4-methylpyridine-3-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound CC1=CC=NC=C1C(=O)N1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 BKOZZQHXWUNDHJ-UHFFFAOYSA-N 0.000 description 1
- NZLAZSMFJXYRLZ-UHFFFAOYSA-N 3-[1-[1-(5,6-dichloropyridine-3-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound N1=C(Cl)C(Cl)=CC(C(=O)N2CCC(CC2)N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)=C1 NZLAZSMFJXYRLZ-UHFFFAOYSA-N 0.000 description 1
- XIYLHUNLVBZKOC-UHFFFAOYSA-N 3-[1-[1-(5-methylpyridine-3-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound CC1=CN=CC(C(=O)N2CCC(CC2)N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)=C1 XIYLHUNLVBZKOC-UHFFFAOYSA-N 0.000 description 1
- ZKFISSDYSGRNHP-UHFFFAOYSA-N 3-[1-[1-(6-piperidin-1-ylpyrazine-2-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C(N=1)=CN=CC=1N1CCCCC1 ZKFISSDYSGRNHP-UHFFFAOYSA-N 0.000 description 1
- PZNNQRBXTJYDMV-UHFFFAOYSA-N 3-[1-[1-(6-pyrrolidin-1-ylpyrazine-2-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C(N=1)=CN=CC=1N1CCCC1 PZNNQRBXTJYDMV-UHFFFAOYSA-N 0.000 description 1
- FSGMOMOEXGTYMY-UHFFFAOYSA-N 3-[1-[1-(furan-2-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C1=CC=CO1 FSGMOMOEXGTYMY-UHFFFAOYSA-N 0.000 description 1
- OHTTWWAOVPJXQF-UHFFFAOYSA-N 3-[1-[1-(pyridine-2-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C1=CC=CC=N1 OHTTWWAOVPJXQF-UHFFFAOYSA-N 0.000 description 1
- NBZDLBRQRNVFRK-UHFFFAOYSA-N 3-[1-[1-(pyridine-4-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C1=CC=NC=C1 NBZDLBRQRNVFRK-UHFFFAOYSA-N 0.000 description 1
- DKCWIJDTMFEPNC-UHFFFAOYSA-N 3-[1-[1-[6-(dimethylamino)pyrazine-2-carbonyl]piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound CN(C)C1=CN=CC(C(=O)N2CCC(CC2)N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)=N1 DKCWIJDTMFEPNC-UHFFFAOYSA-N 0.000 description 1
- SQUOITUNNIMFMW-UHFFFAOYSA-N 3-[1-[1-[6-(methylamino)pyrazine-2-carbonyl]piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound CNC1=CN=CC(C(=O)N2CCC(CC2)N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)=N1 SQUOITUNNIMFMW-UHFFFAOYSA-N 0.000 description 1
- CGFZFVWXNZVLTQ-UHFFFAOYSA-N 3-[1-[[1-(pyridine-3-carbonyl)piperidin-4-yl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(CN2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C1=CC=CN=C1 CGFZFVWXNZVLTQ-UHFFFAOYSA-N 0.000 description 1
- KJWGWYSMAGDHFA-UHFFFAOYSA-N 3-[1-[[1-(pyridine-4-carbonyl)piperidin-4-yl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1CC(CN2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CCN1C(=O)C1=CC=NC=C1 KJWGWYSMAGDHFA-UHFFFAOYSA-N 0.000 description 1
- ZAGZIOYVEIDDJA-UHFFFAOYSA-N 3-aminopyrazine-2-carboxylic acid Chemical compound NC1=NC=CN=C1C(O)=O ZAGZIOYVEIDDJA-UHFFFAOYSA-N 0.000 description 1
- SMMQWWFJMRLVIB-UHFFFAOYSA-N 4-(2-aminoanilino)cyclohexan-1-one;ethene Chemical group C=C.NC1=CC=CC=C1NC1CCC(=O)CC1 SMMQWWFJMRLVIB-UHFFFAOYSA-N 0.000 description 1
- WWJHRSCUAQPFQO-UHFFFAOYSA-M 4-DAMP methiodide Chemical compound [I-].C1C[N+](C)(C)CCC1OC(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 WWJHRSCUAQPFQO-UHFFFAOYSA-M 0.000 description 1
- ZZLCFHIKESPLTH-UHFFFAOYSA-N 4-Methylbiphenyl Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 description 1
- RKTQEVMZBCBOSB-UHFFFAOYSA-N 4-aminocyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1CCC(O)CC1 RKTQEVMZBCBOSB-UHFFFAOYSA-N 0.000 description 1
- OTCYOBLTAQTFPW-UHFFFAOYSA-N 4-aminocyclohexan-1-one Chemical compound NC1CCC(=O)CC1 OTCYOBLTAQTFPW-UHFFFAOYSA-N 0.000 description 1
- ZUBDZQFROMAIPT-UHFFFAOYSA-N 4-aminopyrimidine-5-carboxylic acid Chemical compound NC1=NC=NC=C1C(O)=O ZUBDZQFROMAIPT-UHFFFAOYSA-N 0.000 description 1
- DAQOTADXAYOTGQ-UHFFFAOYSA-N 4-fluoro-3-[1-[1-(pyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C1=2C(F)=CC=CC=2NC(=O)N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CN=CN=C1 DAQOTADXAYOTGQ-UHFFFAOYSA-N 0.000 description 1
- GYCPLYCTMDTEPU-UHFFFAOYSA-N 5-bromopyrimidine Chemical compound BrC1=CN=CN=C1 GYCPLYCTMDTEPU-UHFFFAOYSA-N 0.000 description 1
- FNOPMQNUQPAKJC-UHFFFAOYSA-N 5-methyl-3-[1-[1-(pyrimidine-5-carbonyl)piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC(C)=CC=C2NC(=O)N1C(CC1)CCN1C(CC1)CCN1C(=O)C1=CN=CN=C1 FNOPMQNUQPAKJC-UHFFFAOYSA-N 0.000 description 1
- RWGSCFHUIFPLEI-UHFFFAOYSA-N 6-methoxypyrazine-2-carboxylic acid Chemical compound COC1=CN=CC(C(O)=O)=N1 RWGSCFHUIFPLEI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- KLWZBMGAZQBQAY-QAQDUYKDSA-N C(C)(C)(C)OC(=O)N1CCN(CC1)[C@@H]1CC[C@H](CC1)N1C(NC2=C1C=CC=C2)=O Chemical compound C(C)(C)(C)OC(=O)N1CCN(CC1)[C@@H]1CC[C@H](CC1)N1C(NC2=C1C=CC=C2)=O KLWZBMGAZQBQAY-QAQDUYKDSA-N 0.000 description 1
- ITTCDTZPQOHBTK-AQYVVDRMSA-N C(C1=CC=CC=C1)OC(=O)N[C@@H]1CC[C@H](CC1)CN1CCC(CC1)N1C(NC2=C1C=CC=C2)=O Chemical compound C(C1=CC=CC=C1)OC(=O)N[C@@H]1CC[C@H](CC1)CN1CCC(CC1)N1C(NC2=C1C=CC=C2)=O ITTCDTZPQOHBTK-AQYVVDRMSA-N 0.000 description 1
- YCSUZEWEXZWICO-MXVIHJGJSA-N C1CN([C@@H]2CC[C@H](CC2)N2C(NC3=CC=CC=C32)=O)CCC1NC(=O)C1=CC=CN=C1 Chemical compound C1CN([C@@H]2CC[C@H](CC2)N2C(NC3=CC=CC=C32)=O)CCC1NC(=O)C1=CC=CN=C1 YCSUZEWEXZWICO-MXVIHJGJSA-N 0.000 description 1
- AUZUHNRUYQQQHU-HDJSIYSDSA-N C1C[C@@H](N)CC[C@@H]1N1CCC(N2C(NC3=CC=CC=C32)=O)CC1 Chemical compound C1C[C@@H](N)CC[C@@H]1N1CCC(N2C(NC3=CC=CC=C32)=O)CC1 AUZUHNRUYQQQHU-HDJSIYSDSA-N 0.000 description 1
- AUZUHNRUYQQQHU-OKILXGFUSA-N C1C[C@@H](N)CC[C@H]1N1CCC(N2C(NC3=CC=CC=C32)=O)CC1 Chemical compound C1C[C@@H](N)CC[C@H]1N1CCC(N2C(NC3=CC=CC=C32)=O)CC1 AUZUHNRUYQQQHU-OKILXGFUSA-N 0.000 description 1
- 102000017925 CHRM3 Human genes 0.000 description 1
- 101150060249 CHRM3 gene Proteins 0.000 description 1
- PVJDSQZAPVYWQI-KOMQPUFPSA-N Cc(cc1)cc(N2)c1N(C(CC1)CCN1[C@H](CC1)CC[C@@H]1O)C2=O Chemical compound Cc(cc1)cc(N2)c1N(C(CC1)CCN1[C@H](CC1)CC[C@@H]1O)C2=O PVJDSQZAPVYWQI-KOMQPUFPSA-N 0.000 description 1
- NWSRKHZBGUODAJ-UHFFFAOYSA-N Cc(cc1NC=O)ccc1NC(CC1)CCN1C(CC1)CCC1O Chemical compound Cc(cc1NC=O)ccc1NC(CC1)CCN1C(CC1)CCC1O NWSRKHZBGUODAJ-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- BTYBTDGWTAJDDP-WGSAOQKQSA-N O=C1C2=CC=CC=C2C(=O)N1C[C@@H]1CC[C@@H](N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 Chemical compound O=C1C2=CC=CC=C2C(=O)N1C[C@@H]1CC[C@@H](N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 BTYBTDGWTAJDDP-WGSAOQKQSA-N 0.000 description 1
- HICLHPMJLBYMCW-WGSAOQKQSA-N O=C1C2=CC=CC=C2C(=O)N1[C@@H]1CC[C@@H](CN2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 Chemical compound O=C1C2=CC=CC=C2C(=O)N1[C@@H]1CC[C@@H](CN2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 HICLHPMJLBYMCW-WGSAOQKQSA-N 0.000 description 1
- QLYMXWCWASMEMO-UHFFFAOYSA-N OC(CC1)CCC1N(CC1)CCC1N(c(cccc1)c1N1)C1=O Chemical compound OC(CC1)CCC1N(CC1)CCC1N(c(cccc1)c1N1)C1=O QLYMXWCWASMEMO-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000206607 Porphyra umbilicalis Species 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- BHIIGRBMZRSDRI-UHFFFAOYSA-N [chloro(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(Cl)OC1=CC=CC=C1 BHIIGRBMZRSDRI-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000004323 axial length Effects 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940092732 belladonna alkaloid Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- PVYPHUYXKVVURH-UHFFFAOYSA-N boron;2-methylpropan-2-amine Chemical compound [B].CC(C)(C)N PVYPHUYXKVVURH-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- GCSAXWHQFYOIFE-UHFFFAOYSA-N dipyridin-2-yl carbonate Chemical compound C=1C=CC=NC=1OC(=O)OC1=CC=CC=N1 GCSAXWHQFYOIFE-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- NJSUFZNXBBXAAC-UHFFFAOYSA-N ethanol;toluene Chemical compound CCO.CC1=CC=CC=C1 NJSUFZNXBBXAAC-UHFFFAOYSA-N 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- GCGQBUJYXVSZBS-UHFFFAOYSA-N ethyl 2-aminopyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(N)N=C1 GCGQBUJYXVSZBS-UHFFFAOYSA-N 0.000 description 1
- YIGWCGNRGRDQRX-UHFFFAOYSA-N ethyl 4-(2-amino-4-methylanilino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=CC=C(C)C=C1N YIGWCGNRGRDQRX-UHFFFAOYSA-N 0.000 description 1
- ZXYAWONOWHSQRU-UHFFFAOYSA-N ethyl 4-oxocyclohexanecarboxylate Chemical compound CCOC(=O)C1CCC(=O)CC1 ZXYAWONOWHSQRU-UHFFFAOYSA-N 0.000 description 1
- WHQLQYRFIHPMNA-UHFFFAOYSA-N ethyl acetate;oxolane Chemical compound C1CCOC1.CCOC(C)=O WHQLQYRFIHPMNA-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- SXWRTZOXMUOJER-UHFFFAOYSA-N hydron;piperidin-4-one;chloride;hydrate Chemical compound O.Cl.O=C1CCNCC1 SXWRTZOXMUOJER-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 230000004315 low visual acuity Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001383 methylscopolamine Drugs 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960002511 phenobarbital sodium Drugs 0.000 description 1
- WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- FFNMBRCFFADNAO-UHFFFAOYSA-N pirenzepine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 FFNMBRCFFADNAO-UHFFFAOYSA-N 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000009596 postnatal growth Effects 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical class [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000010344 pupil dilation Effects 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- DXBWJLDFSICTIH-UHFFFAOYSA-N pyrazine-2-carbaldehyde Chemical group O=CC1=CN=CC=N1 DXBWJLDFSICTIH-UHFFFAOYSA-N 0.000 description 1
- NIPZZXUFJPQHNH-UHFFFAOYSA-N pyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- JUSIWJONLKBPDU-UHFFFAOYSA-N pyridazine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NN=C1 JUSIWJONLKBPDU-UHFFFAOYSA-N 0.000 description 1
- HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 description 1
- CDRNYKLYADJTMN-UHFFFAOYSA-N pyridine-3-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CN=C1 CDRNYKLYADJTMN-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- FVLAYJRLBLHIPV-UHFFFAOYSA-N pyrimidin-5-amine Chemical compound NC1=CN=CN=C1 FVLAYJRLBLHIPV-UHFFFAOYSA-N 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- YPOXGDJGKBXRFP-UHFFFAOYSA-N pyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-N 0.000 description 1
- FREJAOSUHFGDBW-UHFFFAOYSA-N pyrimidine-5-carbaldehyde Chemical group O=CC1=CN=CN=C1 FREJAOSUHFGDBW-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000004256 retinal image Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- KVGWDFGQNKSRPT-UHFFFAOYSA-N tert-butyl 2-[2-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]anilino]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC=C1NC1N(C(=O)OC(C)(C)C)CCCC1 KVGWDFGQNKSRPT-UHFFFAOYSA-N 0.000 description 1
- BZRSXTKLJMZVOI-UHFFFAOYSA-N tert-butyl 4-[2-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]anilino]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC=C1NC1CCN(C(=O)OC(C)(C)C)CC1 BZRSXTKLJMZVOI-UHFFFAOYSA-N 0.000 description 1
- NHFVAONVLCETEV-UHFFFAOYSA-N tert-butyl 4-isoquinolin-5-ylpiperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=CC2=CN=CC=C12 NHFVAONVLCETEV-UHFFFAOYSA-N 0.000 description 1
- ZTBNOFSSMFDTHM-UHFFFAOYSA-N tert-butyl n-[(2-aminophenyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC=C1N ZTBNOFSSMFDTHM-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- This invention relates to control of ocular development in general and, more particularly, to the treatment of the eye to prevent and/or arrest the development of myopia (nearsightedness).
- myopia nearsightedness
- myopia Approximately one of every four persons suffer from myopia, i.e., an elongation of the eye along the visual axis.
- myopia afflicts 10% to 75% of the youth of the world, depending upon race, geographic distribution and level of education.
- Myopia is not a trivial maldevelopment of the eye. In its pathologic form, the sclera continues to grow and as result the retina stretches and degenerates resulting in permanent blindness.
- Cycloplegics are topically administered drugs that relax the ciliary muscle of the eye, which is the muscle that focuses the eye by controlling lens dimensions.
- the classic cycloplegic drug is the belladonna alkaloid atropine, available for over a century.
- Atropine is a long-acting non-specific
- ACh neurotransmitter acetylcholine
- Atropine is impractical in that it causes mydriasis (increase of pupil size) and its action on the ciliary muscle to inhibit ocular focusing impairs near visual work like reading.
- the receptors in the iris and ciliary muscle responsible for the side effects of atropine are of the M3 subtype.
- studies have shown that muscarinic receptors in the retina of a variety of non-human species are comprised of m1 , m2 and m4 subtypes. Accordingly, a muscarinic antagonist with low m3 activity would be efficacious in prevention of the development of myopia without the undesirable side effects associated with the use of atropine.
- retinal concentrations of dopamine were found to be reduced during such image deprivation and the ocular administration of a dopamine-related agent, e.g., apomorphine, a dopamine agonist, was found to inhibit or actually prevent the axial enlargement of the eye under conditions ordinarily leading to such enlargement.
- a dopamine-related agent e.g., apomorphine, a dopamine agonist
- Cholinergic receptors are proteins embedded in the wall of a cell that respond to the chemical acetylcholine. Particularly, it is now known that the cholinergic receptors are subdivided into nicotinic and muscarinic receptors and that the muscarinic receptors are not all of the same type. Recent literature indicates that there are at least five types of cholinergic muscarinic receptors (types ml through m5). Receptors of type ml are those present in abundance and thought to be enriched in the brain neural tissue and neural ganglia. The other receptors are concentrated in other tissues such as the heart, smooth muscle tissue or glands. While many others are at least five types of cholinergic muscarinic receptors (types ml through m5). Receptors of type ml are those present in abundance and thought to be enriched in the brain neural tissue and neural ganglia. The other receptors are concentrated in other tissues such as the heart, smooth muscle tissue or glands. While many others
- pharmacological agents interacting with muscarinic receptors influence several types, some agents are known to have a major effect on a single type of receptor with relative selectivity and other agents can have a relatively selective effect on a different single receptor. Still other agents may have a significant effect on more than one or even all types of receptors.
- dihydrochloride are anticholinergic, antimuscarinic, and relatively selective for Ml receptors. See U.S. Pat. No. 5,122,522. It is also known that 4-DAMP (4-diphenylacetoxy-N-methylpiperadine methiodide) is a relatively selective antagonist for smooth muscle (ordinarily called M3 type but variously called type M2 or M3, as the current classification of receptors is in flux). Pirenzepine, being primarily an M1 antagonist, inhibits axial elongation, but is far less effective at pupil dilation than atropine or another cycloplegic agent. This makes it possible to suppress the development of myopia
- This invention is concerned with novel 1,3-dihydro-1 - ⁇ 1 -[piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-ones and 1,3-dihydro-1 - ⁇ 4-amino-1 -cyclohexyl ⁇ -2H-benzimidazol-2-ones, their compositions and method of use.
- the novel compounds are selective muscarinic antagonists of the m1 , m2, and m4 subtypes with low activity at the m3 subtype.
- the compounds have good ocular
- the compounds are effective for the treatment and/or prevention of myopia.
- novel compounds of this invention are represented by the structural formula: wherein:
- N is nitrogen
- O oxygen
- NBCONB2 CB 2 COCB 2 , CB 2 CONB, NBCOCB 2 , or OB
- W is O or H 2 ;
- B is H, Me, Et, Pr, iPr, CH 2 OH, CO 2 Me, CO 2 Et,
- Q is phenyl or heterocycle ring unsubstimted or
- R is independently taken from H, small alkyl , branched alkyl, halo, alkoxy, OH, amino, dialkylamino, or alkyla
- heterocycle or heterocyclic as used herein except where noted, represents a stable 5- to 7- membered
- heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
- heterocyclic rings include pyridine, pyrazine, pyrimidine, pyridazine, triazine, imidazole, pyrazole, triazole, quinoline.
- alkyl is intended to include both branched and straight chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms (Me is methyl, Et is ethyl, Pr is propyl, Bu is butyl).
- alkoxy represents an alkyl group of indicated carbon atoms attached through an oxygen linkage.
- alkylamino represents an alkyl group of indicated carbon atoms attached through a nitrogen atom linkage.
- dialkylamino represents two alkyl groups of indicated carbon atoms attached through a nitrogen atom linkage.
- small alkyl is intended to indicate those alkyls with C1 to C4 carbon atoms, either branched or linear in connection.
- alkylsulfonyl represents an alkyl group of indicated carbon atoms attached through an sulfonyl (SO 2 ) linkage.
- halo represents fluoro, chloro, bromo or iodo.
- the pharmaceutically acceptable salts of the compounds of formula I include the conventional non-toxic salts or the quarternary ammonium salts of the compounds of formula I formed e.g. from non-toxic inorganic or organic acids.
- such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic,
- phosphoric, nitric and the like and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
- the pharmaceutically acceptable salts of the present invention can be synthesized from the compounds of formula I which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base or acid with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.
- the compounds of the present invention may have asymmetric centers and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention.
- novel compounds of this invention are prepared by the following non-limiting procedures:
- the reaction is preferably carried out at room temperature (20- 30°C) at a pH in the range of 2-7 (acidic) by the addition of glacial acetic acid or hydrochloric acid.
- the reaction is preferably carried out at room temperature (20-30°C) at a pH in the range of 2-7 (acidic) by the addition of glacial acetic acid or hydrochloric acid.
- NHCO 2 CH 2 Ph NHCO 2 C(CH 3 ) 3 , NHCO 2 CH 3 , NHCO 2 CH 2 CH 3 or N 3 can be used as an intermediate.
- Deprotection by the usual methods hydrogenation or acidic hydrolysis followed by basification
- the preferred compounds can be obtained after isolation and purification.
- the more preferred trans -isomer is either formed selectively by control of the reaction
- novel starting materials of the formula (IV) can be obtained by conventional procedures such as those described in the Examples section.
- the starting materials of the formula (V) are either
- the reaction is preferably carried out at room temperature (20- 30°C) at a pH in the range of 2-7 (acidic) by the addition of glacial acetic acid or hydrochloric acid.
- CO 2 CH 2 CH 3 can be used as an intermediate.
- Deprotection by the usual methods hydrogenation or acidic hydrolysis followed by basification
- the more preferred trans -isomer is either formed selectively by control of the reaction conditions, or separated by chromatography.
- novel starting materials of the formula (IV) can be obtained by conventional procedures such as those described in the Examples section.
- the starting materials of the formula (VI) are either commercially available or can be obtained by conventional
- the reaction is preferably carried out at room temperature (20- 30°C) at a pH in the range of 2-7 (acidic) by the addition of glacial acetic acid or hydrochloric acid.
- Deprotection by the usual methods hydrogenation or acidic hydrolysis followed by basification
- the more preferred transisomer is either formed selectively by control of the reaction conditions, or separated by chromatography.
- novel starting materials of the formula (VII) can be obtained by conventional procedures such as those described in the Examples section.
- the starting materials of the formula (III) are either
- the compounds of the present invention include, but are not limited by the following Tables (1-4).
- the selectivity of the compounds can be measured by radioligand displacement from ml-m5 receptors expressed in Chinese hamster ovary cells (CKO) as described in the Examples section.
- the functional activity of the compounds can be assessed by measuring the agonist induced contractile response on muscle tissue from rabbit vas deferens (M 1 ), the guinea pig left atria (M2), or the guinea pig ileum (M3) as described in the Examples section.
- the functional activity at the human muscarinic receptors can be assessed by measuring agonist induced phosphoinositide hydrolysis in CHO cells expressing the human ml and m3 receptors or agonist inhibition of foskolin-stimulated adenylate cyclase activity in CHO cells expressing the human m2 receptor as described in the Examples section.
- the instant compounds of this invention are useful in treating and/or preventing the development of myopia. Therapy to inhibit axial-elongation myopia during maturation can be
- Eye drops are typically made up at a concentration of active agent between about 0.1 and 2% in the ophthalmic medium.
- a 0.5%-2% solution of the instant muscarinic antagonist in water would be a likely concentration for clinical use.
- a pH of about 4.5 to about 7.5 is expected to be acceptable as an ophthalmic drop and practical in terms of known solubility and stability of piperidines.
- Phosphate buffering is also common for eye drops and is compatible with the instant muscarinic antagonist.
- a common regimen for application of eye drops is one to three times a day spaced evenly throughout waking hours. More effective agents may require fewer applications or enable the use of more dilute solutions.
- ointments and solid inserts are now coming into increased use in clinical practice. These aid the ocular
- muscarinic antagonist might prevent or inhibit the development of permanent or persistent amblyopia in maturing humans with decreased likelihood of sensitization of the eye. It is also possible that humans who have already developed amblyopia from other or even unknown causes might be aided by similar therapeutic treatment with the aforementioned agents.
- Step 1 A mixture of 100 g 4-piperidone hydrochloride hydrate, 1 L ether, 300 mL of water, 500 mL of saturated aqueous
- Step 2 A mixture of 20.6 g N-t-butyloxycarbonyl-4-piperidone, 15 g of 4-(2-oxo-1-benzimidazolinyl)piperidine, 300 mL of 1 ,2-dichloroethane, 4.2 mL of glacial acetic acid and 24 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 500 mL chloroform and 500 mL saturated aqueous Na 2 CO 3 and the layers separated. The aqueous layer was extracted with 2 X 250 mL of chloroform and the combined organic layers dried over MgSO 4 and concentrated under reduced pressure.
- Step 3 A stirred solution of 4 g of 1,3-dihydro-1- ⁇ 1 -[ 1 -(t-butyloxycarbonyl)piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one in 150 mL of 1N HCl was heated to reflux for 4 h, cooled and
- Step 4 To a stirred solution of 6 g of 1,3-dihydro-1 - ⁇ 1 -[ 1 -piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one dihydrochloride salt and 20 mL of triethylamine in 500 mL of dichloromethane was added 3 g of pyrimidine-5-carboxylic acid chloride. After 2 h, 50 mL of dilute aqueous ammonia was added and the mixture stirred for an additional 30 min. The organic layer was separated, the aqueous layer extracted with two additional 200 mL portions of chloroform and the combined organic extracts dried over MgS O 4 and concentrated under reduced pressure.
- Step 1 A mixture of 69 g of 4-chloro-3-nitro-toluene, 50 g of ethyl 4-amino-1 -piperidinecarboxylate, 24 g of sodium carbonate, 0.1 g of sodium iodide and 120 mL of cyclohexanol was heated to 150°C for 72 h. After cooling the cyclohexanol was distilled off under reduced pressure and the residue partitioned between 1 L of ethyl acetate and 1 L of water. The organic extract was dried over MgSO 4 and
- Step 2 A mixture of 8.23 g of ethyl 4-(4-methyl-2-nitroanilino)-1-piperidinecarboxylate, 200 mL of tetrahydrofuran , 225 mL of ethanol and 2 g of 5% platinum on carbon was stirred under an atmosphere of hydrogen for 7 h. The catalyst was filtered off and the filtrate concentrated to to a thick oil.
- Step 3 A mixture of 5 g of ethyl 4-(5-methyl-2-oxo-1 -benzimidazolinyl)piperidine-1 -carboxylate and 20 mL of 2N NaOH was heated under reflux for 12 h. The resulting solution is cooled and stirred for for 30 minutes with 5 g of ammonium chloride and extracted with three 200 mL portions of chloroform. The combined organic extracts were dried over MgSO 4 , concentrated under reduced pressure and triturated with ether. The solid product 4-(5-methyl-2-oxo-1-benzimidazolinyl)piperidine weighed 3.5 g after drying.
- Step 4 A mixture of 4.5 g N-t-butyloxycarbonyl-4-piperidone, 4.7 g of 4-(5-methyl-2-oxo-1 -benzimidazolinyl)piperidine, 65 mL of 1 ,2-dichloroethane, 1.3 mL of glacial acetic acid and 6.4 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h.
- the reaction mixture was poured into 500 mL chloroform and 500 mL saturated aqueous Na 2 CO 3 and the layers separated. The aqueous layer was extracted with 2 X 250 mL of chloroform and the combined organic layers dried over MgSO 4 and concentrated under reduced pressure.
- Step 5 A stirred solution of 6.18 g of 5-methyl-1,3-dihydro-1 - ⁇ 1 -[ 1 -(t-butyloxycarbonyl)piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one in 200 mL of 1N HCl was heated to reflux for 4 h, cooled and concentrated to dryness. After drying overnight under vacuum, there was obtained 6 g of 5-methyl-1 ,3-dihydro-1 - ⁇ 1-[ 1 -piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one dihydrochloride salt as a white solid.
- Step 6 To a stirred solution of 6 g of 5-methyl-1,3-dihydro-1 - ⁇ 1 -[ 1 -piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one
- Step 1 A mixture of 10 g of 1 ,4-cyclohexanedione mono-ethyleneketal, 13.8 g of 1,2-phenylenediamine, 180 mL of 1 ,2-dichloroethane, 4 mL of glacial acetic acid and 19 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 200 mL chloroform and 200 mL saturated 1N NaOH and the layers separated. The aqueous layer was extracted with 2 X 50 mL of chloroform and the combined organic layers dried over MgSO 4 and concentrated to dryness under reduced pressure.
- Step 2 A mixture of 7 g of the ethylene ketal of 1 ,3-dihydro- 1 -(4-oxocyclohexyl)-2H-benzimidazol-2-one, 100 mL of glacial acetic acid, 50 mL of water and 50 mL of cone. HCl was heated under reflux for 12 h. The mixture was concentrated under reduced pressure, diluted with 100 mL of water and extracted into 3 X 200 mL of CHCl 3 . The combined organic extracts were washed with 100 mL of water, 100 mL of saturated Na 2 CO 3 . dried over MgSO 4 and concentrated under reduced pressure.
- Step 3 A mixture of 1.5 g of 1,3-dihydro-1 -(4-oxocyclohexyl)-2H-benzimidazol-2-one, 1.21 g of tert-butyl-1 -piperazinecarboxylate, 20 mL of 1,2-dichloroethane, 0.4 mL of acetic acid and 1.8 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 500 mL chloroform and 500 mL saturated aqueous Na 2 CO 3 and the layers separated. The aqueous layer was extracted with 2 X 250 mL of chloroform and the combined organic layers dried over MgSO 4 and concentrated under reduced pressure.
- Step 4 A stirred solution of 0.52 g of trans -1 ,3-dihydro-1 - ⁇ 4-[4-(tert -butyloxycarbonyl)piperazin-1-yl]-1-cyclohexyl ⁇ -2H-benzimidazol-2-one in 15 mL of 1N HCl was heated to reflux for 1 h, cooled, basified to pH 10 with 6N NaOH and extracted 2 ⁇ 50 mL of CHCl 3 . The combined extracts were dried over MgSO 4 and concentrated under reduced pressure.
- Step 5 To a stirred solution of 0.044 g of trans -1,3-dihydro-1 - ⁇ 4-(1 -piperazinyl)-1 -cyclohexyl ⁇ -2H-benzimidazol-2-one and 20 mL of triethylamine in 3 mL of dichloromethane was added 0.03 g of pyrimidine-5-carboxylic acid chloride. After 2 h, 5 mL of dilute aqueous ammonia was added and the mixture stirred for an additional 30 min. The organic layer was separated, the aqueous layer extracted with two addtional 20 mL portions of chloroform and the combined organic extracts dried over MgSO 4 and concentrated under reduced pressure.
- Step 1 To a stirred solution of 2.0 g of ethyl 4-amino- 1 -piperidinecarboxylate and 2 mL of triethylamine in 50 mL of
- Step 2 A mixture of 1.2 g of the ethylene ketal of 4-(3-pyridinecarbonylamino)- 1 -piperidinecarboxylate and 20 mL of 6N HCl was heated under reflux for 6 h. The mixture was cooled, extracted with 20 mL of dichloromethane, then basified with 6N NaOH and extracted with 3 X 50 mL of chloroform.
- Step 3 A mixture of 0.13 g of 1 ,3-dihydro-1 -(4-oxocyclohexyl)-2H-benzimidazol-2-one, 0.12 g of 4-(3-pyridinecarbonylamino)piperidine, 5 mL of 1 ,2-dichloroethane, 0.04 mL of glacial acetic acid and 0.161 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 50 mL chloroform and 50 mL saturated aqueous Na 2 CO 3 and the layers separated.
- Step 1 To a stirred solution of 0.108 g of 3-aminomethylpyridine and 0.280 g of di-2-pyridylcarbonate in 5 mL of dichloromethane was added 0.209 mL of triethylamine. After 12 h, the mixture was diluted with 50 mL of dichloromethane and washed with 50 mL of satutrated sodium bicarbonate, dried over MgSO 4 and concentrated under reduced pressure. The residue was filtered through a short column of silica gel , eluting with ethyl acetate ( 100 mL) and the eluate concentrated to dryness.
- Step 2 A mixture of 0.108 g of 1 ,3-dihydro- 1- ⁇ 1-[ 1-piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one, 0.070 g of N-(3-pyridylmethyl)-O-2-pyridylurethane and 0.062 mL of triethylamine in 5 mL of dichloromethane was added 2.07 g of nicotinoyl chloride hydrochloride.
- Step 1 A mixture of 1.5 g of 1 ,3-dihydro-1 -(4-oxocyclohexyl)- 2H-benzimidazol-2-one, 1.21 g of tert-butyl 1 -piperazinecarboxylate, 20 mL of 1 ,2-dichloroethane, 0.40 mL of glacial acetic acid and 1.79 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 50 mL chloroform and 50 mL saturated aqueous Na 2 CO 3 and the layers separated.
- Step 2 A stirred solution of 0.52 g of 1 ,3-dihydro-l - ⁇ trans -4-[4-(tert -butylcarbonyl)piperazin-1 -yl]-1 -cyclohexyl ⁇ -2H-benzimidazol-2-one in 15 mL of 1N HCl was heated to reflux for 1 h, cooled and basified with 6N NaOH. The basic mixture was extracted with 2 X 50 mL portions of chloroform. The combined organic extracts were dried over MgSO 4 and concentrated under reduced pressure.
- Step 3 To a stirred solution of 0.044 g of 1,3-dihydro-1-[trans-4-[ 1-piperazinyl]-1 -cyclohexyl ⁇ -2H-benzimidazol-2-one and 0.2 mL of triethylamine in 3 mL of dichloromethane was added 0.030 g of pyrimidine-5-carboxylic acid chloride. After 2 h, 5 mL of dilute aqueous ammonia was added and the mixture stirred for an additional 30 min. The organic layer was separated, the aqueous layer extracted with two addtional 20 mL portions of chloroform and the combined organic extracts dried over MgSC ⁇ t and concentrated under reduced pressure.
- Step 1 A mixture of 1.5 g of 1,3-dihydro- 1 -(4-oxocyclohexyl)-2H-benzimidazol-2-one, 1.12 g of ethyl 4-amino-1 -piperidinecarboxylate, 20 mL of 1 ,2-dichloroethane, 0.40 mL of glacial acetic acid and 1.79 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 50 mL chloroform and 50 mL saturated aqueous Na 2 CO 3 and the layers separated.
- Step 2 A stirred solution of 1.2 g of 1,3-dihydro-1 - ⁇ trans -4-[ 1-ethoxycarbonyl-4-piperidinylamino]-1-cyclohexyl ⁇ -2H-benzimidazol-2- one in 20 mL of 6N HCl was heated to reflux for 12 h, cooled and basified with 6N NaOH. The basic mixture was extracted with 2 X 50 mL portions of chloroform. The combined organic extracts were dried over MgSO 4 and concentrated under reduced pressure.
- Step 3 To a stirred solution of 0.050 g of 1,3-dihydro-1- ⁇ trans-4-[4-piperidinylamino]-1-cyclohexyl ⁇ -2H-benzimidazol-2-one and 0.023 mL of triethylamine in 1.5mL of dichloromethane was added 0.024 g of nicotinoyl chloride hydrochloride. After 12 h, 20 mL of saturated sodium carbonate was added, the organic layer was separated, and the aqueous layer extracted with two addtional 20 mL portions of chloroform. The combined organic extracts dried over MgSO 4 and concentrated under reduced pressure. Chromatography over silica gel eluting with 10% methanol/10% cone.
- Step 1 A mixture of trans -4-aminocyclohexanol hydrochloride
- Step 2 To a stirred solution of oxalyl chloride (0.83 g) in dry dichloromethane (15 mL) at -60 °C was added dimethylsulfoxide (1.0 mL) in dichloromethane (3 mL) dropwise. The reaction mixture was stirred at -60 °C for 10 min, then N-tert -butyloxycarbonyl-trans -4- aminocyclohexanol (1.28 g) in dichloromethane (70 mL) was added over 15 min. The resulting mixture was stirred at -60 °C for a further 15 min, then triethylamine (4.2 mL) was added and the solution was allowed to warm to room temperature.
- Step 3 A mixture of N-tert -butyloxycarbonyl-4-aminocyclohexanone (1.32 g), 4-(2-keto-1-benzimidazolinyl)piperidine ( 1.48 g), sodium triacetoxyborohydride (1.97 g), acetic acid (0.35 mL), 1 ,2-dichloroethane (50 mL) and tetrahydrofuran (60 mL) was stirred at room temperature for 3 days. Saturated aqueous Na 2 CO 3 (30 mL) and H 2 O (30 mL) were added and the mixture was extracted with
- Step 4 The mixture of cis and trans isomers isolated in Step 3 (0.85 g) was stirred in ethyl acetate (100 mL) at 0 °C and gaseous HCl was bubbled in until the mixture was saturated with the acid. Stirring was continued for 20 min, then the reaction mixture was concentrated in vacuo. The residue was dissolved in chloroform, washed with saturated aqueous Na 2 CO 3 , and the organic layer was dried over MgSO 4 and evaporated under reduced pressure.
- Step 5 To the mixture of cis and trans isomers isolated in Step 4 (90 mg) was added tetrahydrofuran (3 mL), dimethylformamide (2 mL), triethylamine (0.12 mL) and nicotinoyl chloride hydrochloride (76 mg). The reaction mixture was stirred at room temperature for 18 h then concentrated to dryness under reduced pressure.
- Step 1 To 1 mL of benzyl alcohol cooled in an ice bath was added 0.1 g of 60% sodium hydride oil dispersion. After 15 min., 0.1 g of 6-chloro-2-pyrazinoic acid was added. The mixture was stirred at room temperature forl h, then acidified with 2 mL of 1 N HCl. The mixture was cooled in an ice bath and the white precipitate collected by filtration.
- Step 2 From 1,3-dihydro-1- ⁇ 1-[1 -piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one dihydrochloride salt and 6-benzyloxy-2- pyrazinoic acid using the procedure described for Example 3, there was obtained 1 ,3-dihydro-1- ⁇ 1-[ 1-(6-benzyloxy-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one as a white solid: 1 H NMR (400 MHz, CDCI 3 ) 9.98 (s, 1H), 8.46 (m, 1H), 8.36 (m, 1H), 7.47-7.05 (m, 9H), 5.43 (m, 2H), 4.81 (br s, 1H), 4.39 (br s, 1H), 3.9 (br s, 1H), 2.85 (m, 1H), 2.65 (m, 1H), 2.46 (m, 4
- Step 1 A mixture of 0.15 g of 1,3-dihydro-1- ⁇ 1-[1-(6-chloro-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one, 0.26 g of sodium azide and 5 mL of anhydrous N,N-dimethylformamide was stirred for 24 h, then concentrated to dryness under reduced pressure. The residue was partitioned between 50 mL of chloroform and 5 mL of saturated sodium carbonate and the organic extracts dried over MgSO 4 .
- Step 2 The crude 1 ,3-dihydro-1- ⁇ 1 -[1-(6-azido-2-pyrazinecarbonyl)piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one was hydrogenated under 1 atm. of hydrogen in 20 mL of ethanol over 0.05 g of 5% palladium on carbon. The catalyst was removed by filtration and the filtrate concentrated to dryness under reduced pressure. Preparative thin layer chromatography using 20%
- CDCI 3 9.25 (s, 1H), 8.90 (s, 2H), 7.98 (s, 1H), 7.61 (s, 1H), 7.3 (m, 1H), 7.1 -7.05 (m, 3H), 4.8 (m, 1H), 4.4 (m, 1H), 4.1 (m, 1H), 3.1 (m, 2H), 2.9 (m, 2H), 2.77-2.35 (m, 4H), 2.0-1.5 (m, 7H).
- CDCI 3 9.52 (s, 1H), 9.33 (s, 1H), 9.22 (m, 1H), 7.5 (m, 1H), 7.27 (m, 1H), 7.12-7.04 (m, 3H), 4.77 (m, 1H), 4.35 (br s, 1H), 3.6 (m, 1H), 3.1 (m. 2H), 2.9 (m, 1H), 2.65 (m, 1H), 2.44 (m, 4H), 2.1 (br s, 1H), 1.87 (m, 4H), 1.6 (m, 2H).
- the dihydrochloride salt was precipitated from ethanol/ether: Analysis calculated for C 22 H 26 N 6 O 2 ⁇ 0.62
- the dihydrochloride salt was precipitated from ethanol/toluene: Analysis calculated for C 24 H 30 N 6 O 2 ⁇ 1.6 H 2 O ⁇ 0.4 CH 3 C 6 H 5 : C: 56.16, H: 6.77, N: 14.66; found C: 56.18, H: 6.37, N: 14.69.
- Step 1 A mixture of 45 g of 2-aminomethylaniline, 60 g of di-tert -butyldicarbonate, 1000 mL of dichloromethane was stirred for 18 h and washed with 500 mL of 2N NaOH. The organic extract was dried over MgSO 4 and concentrated under reduced pressure. Drying under vacuum gave 47 g of 2-(tert -butoxycarbonylaminomethyl)aniline as a white crystalline solid.
- Step 2 A mixture of 15.5 g of 1- ⁇ tert -butoxycarbonyl
- Step 3 To a stirred solution of 27.1 g of tert -butyl 4-(2-tert-butoxycarbonylaminomethylanilino)-1 -piperidinecarboxylate and 30 mL of triethylamine in 400 mL of dichloromethane was added dropwise 60 mL of a 1.93 M solution of phosgene in toluene. After stirring for 12 h, 200 mL of 1N NaOH was added. The mixture was shaken, and the organic layer separated, dried over MgSO 4 and concentrated under reduced pressure.
- Step 4 A stirred solution of 25 g of 1 ,3-dihydro-1 -[1 -tert
- Step 5 A mixture of 0.52 g of 1 ,3-dihydro-1-[piperidin-4-yl]-1H-3,4-dihydroquinazolin-2-one, 0.65 g of N-t-butyloxycarbonyl-4-piperidone, 10 mL of 1 ,2-dichloroethane, 0.3 mL of glacial acetic acid and 1 g of sodium triacetoxyborohydride was stirred at room
- Step 6 A stirred solution of 0.9 g of 1 ,3-dihydro- 1 - ⁇ 1 -[1-(tert-butyloxycarbonyl)piperidin-4-yl]piperidin-4-yl ⁇ - 1 H-3,4-dihydroquinazolin-2-one in 40 mL of 1N HCl was heated to reflux for 6 h, cooled and concentrated to dryness. After drying overnight under vacuum, there was obtained 0.58 g of 1,3-dihydro-1 - ⁇ 1-[piperidin-4-yl]piperidin-4-yl ⁇ -1H-3,4-dihydroquinazolin-2-one dihydrochloride salt as a white solid.
- Step 7 To a stirred solution of 0.58 g of 1 ,3-dihydro-1- ⁇ 1- [piperidin-4-yl]piperidin-4-yl ⁇ -1H-3,4-dihydroquinazolin-2-one dihydrochloride salt and lmL of triethylamine in 50 mL of
- dichloromethane was added 0.3 g of pyrimidine-5-carboxylic acid chloride. After 2 h, 50 mL of dilute aqueous ammonia was added and the mixture stirred for an additional 30 min. The organic layer was separated, the aqueous layer extracted with two additional 50 mL portions of chloroform and the combined organic extracts dried over MgSO 4 and concentrated under reduced pressure.
- Step 1 To a stirred mixture of 1.1 g of 5-(1 -aminoethyl)pyrimidine (O. Cervinska and P. Malon, Coll. Czechoslov. Chem. Commun. 1977, 42 , 3464-72.), 17 mL of ethanol and 1.36 g of K 2 CO 3 heated to reflux was added dropwise over 30 min, a solution of 4 g of 1 ,1 -dimethyl-4oxopiperidinium iodide in 70 mL of water. When the addition was complete, the mixture was heated under reflux for an additional 2 h, cooled, basified to pH 9 with K 2 CO 3 and extracted with 5 times with 50 mL portions of methylene chloride. The combined organic extracts were dried over MgSO 4 and concentrated under reduced pressure.
- 5-(1 -aminoethyl)pyrimidine O. Cervinska and P. Malon, Coll. Czechoslov. Chem. Commun. 1977, 42 , 3464-72.
- Step 2 A mixture of 0.24 g of 1 -( 1-(5-pyrimidinyl)-ethyl)-4-oxopiperidine, 0.24 g of 1-(4-piperidinyl) benzimidazol-2H-one, 4 mL of 1 ,2-dichloroethane, 0.12 mL of glacial acetic acid and 0.45 g of sodium triacetoxyborohydride was stirred at room temperature for 48 h. The reaction mixture was poured into 100 mL dichloromethane and 25 mL saturated aqueous Na 2 CO 3 and the layers separated.
- the bis-maleate salt Analysis calculated for C 23 H 29 ClN 6 O ⁇ 2 C 4 H 4 O 4 : C:55.31, H: 5.54, N: 12.49; found C: 55.41, H: 5.54, N: 12.60.
- Step 1 A mixture of 5 g of 1 ,4-cyclohexanedione mono-ethyleneketal, 4.3 g of 1 ,3-dihydro-1 -(4-piperidinyl)-benzimidazol-2H-one, 75 mL of 1 ,2-dichloroethane, 1.2 mL of acetic acid and 5.45 g of sodium
- triacetoxyborohydride was stirred at room temperature for 48 h.
- the reaction mixture was poured into 500 mL chloroform and 500 mL saturated aqueous Na 2 CO 3 and the layers separated.
- the aqueous layer was extracted with 2 X 250 mL of chloroform and the combined organic layers dried over MgSO 4 and concentrated under reduced pressure.
- Step 2 A mixture of 7.0 g of the ethylene ketal of 1 ,3-dihydro-1 - ⁇ 1 -[4-oxocyclohex-1-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one, 80 mL of glacial acetic acid, 80 mL of water and 20 mL of cone. HCl was heated under reflux for 2 h, then allowed to cool ovemight. The mixture was concentrated under reduced pressure, diluted with 100 mL of saturated Na 2 CO 3 and extracted into 3 X 200 mL of CHCl 3 . The combined organic extracts were dried over MgSO 4 and concentrated under reduced pressure.
- Step 1 A mixture of 0.10 g of trans -1 ,3-dihydro-1 - ⁇ 4-(1 - piperazinyl)-1 -cyclohexyl ⁇ -2H-benzimidazol-2-one, 0.037 mL of 3-pyridinecarboxaldehyde, 15 mL of 1 ,2-dichloroethane, 0.10 mL of glacial acetic acid and 0.1 1 g of sodium triacetoxyborohydride was stirred at room temperature for 24 h. The reaction mixture was poured into 10 mL dichloromethane and 10 mL saturated aqueous NaHCO 3 and the layers separated.
- Step 1 A mixture of ethyl 4-oxocyclohexanecarboxylate (1.86 g), 4-(2-oxo-1 -benzimidazolinyl)piperidine ( 1.98 g), 1 ,2-dichloroethane (40 mL), glacial acetic acid (0.52 mL) and sodium triacetoxyborohydride (3.47 g) was stirred at room temperature for 72 h. The reaction mixture was poured into dichloromethane (50 mL) and saturated
- Step 2 To a stirred solution of the cis and trans isomers of ethyl 1-[4-(2-keto-1 -benzimidazolinyl)piperidin- 1-yl]cyclohexane-4-carboxylate (2.16 g) in dry toluene (150 mL) at -90 °C under argon, was added diisobutylaluminum hydride (1 1.6 mL of a 1.5 M solution in toluene). The reaction mixture was stirred at -90 °C for 1h, then quenched with methanol (1 mL) followed by saturated sodium potassium tartrate (50 mL).
- Step 3 To a stirred solution of 5-bromopyrimidine (3.98 g) in 1 : 1 diethyl ether; tetrahydrofuran (120 mL) at -1 10 °C under argon, was added n-butyllithium (10.4 mL of a 1.6 M solution in hexanes) at such a rate that the temperature was maintained at -1 10 °C.
- Step 1 To a stirred solution of oxalyl chloride (68 mg) in dry
- Step 1 A mixture of 1 ,3-dihydro-1 - ⁇ 1 -[4-oxocyclohex-1 -yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one (200 mg), 3-aminopyridine (29 mg), 1 ,2-dichloroethane (1.5 mL), acetic acid (0.087 mL) and sodium
- Step 1 Sodium borohydride (0.69 g) was added in portions to a stirred solution of acetylpyrazine (1.49 g) in ethanol (300 mL) at 0 °C. The mixture was allowed to warm to room temperature and stirred for 20 min, then water (100 mL) was added and the mixture adjusted to pH 7 with 1 N hydrochloric acid. The neutralized solution was concentrated in vacua to a volume of 200 mL, saturated with sodium chloride, and extracted with ethyl acetate (3 X 500 mL). The organic extracts were dried (Na 2 SO 4 ) and concentrated to give a solid which was washed with dichloromethane (4 X 100 mL). The dichloromethane washings were concentrated to give 2-(1 -hydroxyethyl)pyrazine (1.38 g) as a colorless oil.
- Step 2 To a stirred solution of 2-( 1 -hydroxyethyl)pyrazine (0.859 g) and diphenylphosphoryl azide (2.48 g) in dry toluene (12 mL) at 0 °C, under argon, was added 1 ,8-diazabicyclo[5.4.0]undec-7-ene ( 1.35 mL) dropwise. The resulting mixture was allowed to warm slowly to room temperature and stirred for 22 h then quenched with water (8 mL). The organic layer was removed and the aqueous phase extracted with 10 mL ethyl acetate.
- Step 3 2-(1-Azidoethyl)pyrazine (0.77 g) and 10% palladium on carbon (0.075 g) were stirred in ethanol (40 mL) under an atmosphere of hydrogen at room temperature for 2 h. The mixture was filtered through a pad of celite and the filtrate concentrated under reduced pressure to yield 2-(1-aminoethyl)pyrazine (0.56 g) as a pale oil
- Step 4 To a stirred mixture of 2-(1 -aminoethyl)pyrazine (225 mg), ethanol (10 mL) and K 2 CO 3 (72 mg) heated to reflux was added dropwise over 30 min, a solution of 4 g of 1 ,1 -dimethyl-4-oxopiperidinium iodide (2.1 g) in water (36 mL). When the addition was complete, the mixture was heated under reflux for an additional 2 h, cooled, basified to pH 10 with Na 2 CO 3 and extracted with ethyl acetate (3 X 100 mL). The combined organic extracts were dried over MgSO 4 and concentrated under reduced pressure.
- Step 5 A mixture of 1 -(1-(2-pyrazinyl)-ethyl)-4-oxopiperidine (37 mg), 4-(2-oxo-1 -benzimidazolinyl)piperidine (41 mg), 1 ,2-dichloroethane (0.75 mL), glacial acetic acid (0.01 1 mL) and sodium triacetoxyborohydride (60 mg) was stirred at room temperature for 48 h. The reaction mixture was poured into dichloromethane (5 mL) and saturated aqueous Na 2 CO 3 (3 mL) and the layers separated.
- Step 1 Sodium borohydride (1.75 g) was added in portions to a stirred solution of ace tylpyri dine (12.1 g) in ethanol (100 mL) at 0 °C. The mixture was allowed to warm to room temperature and stirred for 20 min, then concentrated under reduced pressure to remove ethanol. The thick residue was diluted with 300 mL of dichloromethane, 25 mL of water and 5 mL of 20% NaOH. Thed aqueous layer was saturated with sodium chloride,and extracted with ethyl acetate (4 X 150 mL). The combined organic extracts were dried (MgSO 4 ) and concentrated.
- Step 2 A mixture of 5 g of 3-( 1-hydroxyethyl)pyridine, 80 mL of t-butylmethylether, 0.85 g of lipase from Pseudom ⁇ nas fluorescens on Celite® (30 wt%, prepared as described by D. Bianchi, P. Cesti and E. Battistel, J. Org. Chem. 1988, 53 , 5531 -34) and 2.0 mL of acetic anhydride was allowed to stir in a stoppered flask for 24 h. The mixture was filtered and concentrated under reduced pressure.
- Step 3 To a stirred solution of 1.7 g of 3-(1 'S-hydroxyethyl)pyridine and 4.7 g of diphenylphosphoryl azide 20 mL of dry tetrahydrofuran cooled to 0 °C, was added 3.4 g of 1 ,8-diazabicyclo[5.4.0]undec-7-ene. The resulting mixture was allowed to warm to room temperature for 48 h., then loaded on a 10 ⁇ 15 cm column of silica gel.
- Step 5 To a stirred mixture of 1.5 g of 3-( 1 'R-aminoethyl)pyridine, 50 mL of ethanol and 1.54 g of K 2 CO 3 heated to reflux was added dropwise over 40 min a solution of 4.5 g of 1 -ethyl-1 -methyl-4-oxopiperidinium iodide in water (80 mL). When the addition was complete, the mixture was heated under reflux for an additional 30 min, cooled and extracted with 3 X 100 mL portions of chloroform. The combined organic extracts were dried over MgSO 4 and concentrated under reduced pressure.
- Step 6 A mixture of 1 -( 1'R-(3"-pyridinyl)-ethyl)-4-oxopiperidine (250 mg), 4-(2-oxo-1 -benzimidazolinyl)piperidine (530 mg), 1 ,2-dichloroethane (7 mL), glacial acetic acid (0.2 mL) and sodium
- the citrate salt Analysis calculated for C 24 H 31 N 5 O ⁇ 1.5 C 6 H 8 O 7 : C: 57.13, H: 6.25, N: 10.10 found C: 57.48, H: 6.39, N: 10.35.
- Step 1 To a stirred solution of 4.06 g of 5-pyrimidineacetic acid (F. Zymalkowski and E. Reimann, Arch. Pharm. 1966 299 362-7) and triethylamine (6.55 g) in methylene chloride (150 mL) at 0 °C was added ethyl chloroformate (6.38 g) followed by 4-dimethylaminopyridine (0.72 g). The mixture was stirred at 0 °C for 1 h, then the solution was diluted with methylene chloride (200 mL) and saturated ammonium chloride ( 150 mL) was added. After removal of the organic phase, the aqueous layer was extracted with methylene chloride (2 X 200 mL) and the combined organic extracts were dried over MgSO 4 and concentrated to give 7.33 g of a crude oil.
- 5-pyrimidineacetic acid F. Zymalkowski and E. Reimann, Arch. Pharm. 1966 299 362-7
- Step 3 A mixture of ethyl 2-methyl-2-(5-pyrimidinyl)propionate (4.64 g), 1.0 N lithium hydroxide (26 mL) and THF ( 100 mL) was heated to reflux under argon for 26 h. The mixture was allowed to cool, adjusted to pH 7 with acetic acid, and concentrated to dryness to give 4.1 1 g of lithium 2-methyl-2-(5-pyrimidinyl)propionate as a pale solid.
- Step 4 A mixture of lithium 2-methyl-2-(5-pyrimidinyl)propionate (4.1 1 g), diphenylphosphoryl azide (13.2 g), triethylamine (4.86 g) and anhydrous tert-butyl alcohol (100 mL) was heated to reflux for 6 h, then allowed to cool and concentrated in vacuo. The residue was partitioned between chloroform (250 mL) and water ( 100 mL), and the chloroform was extracted, dried (MgSO 4 ) and evaporated under reduced pressure. Chromatography on silica gel, eluting with
- Step 5 The crude 2-(5-pyrimidinyl)-2-propylisocyanate was treated with a mixture of 1.0 N sodium hydroxide (26 mL), water (20 mL) and THF ( 100 mL) at 0 °C for 30 min, then the mixture was poured into ethyl acetate (200 mL) and water (100 mL). The aqueous layer was acidified to pH 5 with 10% citric acid, extracted twice with ethyl acetate, and then adjusted to pH 1 1 , saturated with sodium chloride, and extracted with methylene chloride (3 X 250 mL). The combined methylene chloride extracts were dried (Na 2 SO 4 ) and concentrated in vacuo to give 2-(5-pyrimidinyl)-2-propylamine (950 mg) as a colorless oil.
- Step 6 To a stirred mixture of 2-(5-pyrimidinyl)-2-propylamine (660 mg), ethanol (9 mL) and K 2 CO 3 (665 mg) heated to reflux was added dropwise over 30 min, a solution of 1 ,1-dimethyl-4-oxopiperidinium iodide (1.9 g) in water (36 mL). When the addition was complete, the mixture was heated under reflux for an additional 2 h, cooled, basified to pH 10 with Na 2 CO 3 and extracted with ethyl acetate (3 ⁇ 100 mL). The combined organic extracts were dried over MgSO 4 and
- Step 7 A mixture of 1 -(2-(5-pyrimidinyl)-prop-2-yl)-4-oxopiperidine ( 1 17 mg), 4-(2-oxo-1 -benzimidazolinyl)piperidine ( 128 mg), 1 ,2-dichloroethane (2.5 mL), glacial acetic acid (0.031 mL) and sodium triacetoxyborohydride ( 170 mg) was stirred at room temperature for 48 h. The reaction mixture was poured into dichloromethane (15 mL) and saturated aqueous Na 2 CO 3 (8 mL) and the layers separated.
- the dihydrochloride salt Analysis calculated for C 22 H 29 CI 2 N 5 O 3 S ⁇ 2 HCl ⁇ 0.8 C 7 H 8 ⁇ 2.0 H 2 O C: 53.10, H: 6.36, N: 11.22 found C: 53.02, H: 6.40, N: 11.15.
- Step 1 A mixture of 0.65 g of ethyl 2-amino-5-pyrimidinecarboxylate (P. Schenone, L. Sansebastiano and L. Mosti, J. Heterocyclic Chem., 1990, 27 , 295-305) , 1.7 g of di-tert-butyldicarbonate and 50 mL of dichloromethane was allowed to stir overnight then concentrated under reduced pressure.
- ethyl 2-amino-5-pyrimidinecarboxylate P. Schenone, L. Sansebastiano and L. Mosti, J. Heterocyclic Chem., 1990, 27 , 295-305
- 1.7 g of di-tert-butyldicarbonate and 50 mL of dichloromethane was allowed to stir overnight then concentrated under reduced pressure.
- Step 3 From 1,3-dihydro-1 - ⁇ 1 -[ 1-piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one dihydrochloride salt and 2-tert-butoxycarbonylamino-5-pyrimidinecarboxylic acid using the procedure described for Example 3, there was obtained 1 ,3-dihydro- 1 - ⁇ 1 -[ 1 -(2-tert-butoxycarbonylamino-5-pyrimidinecarbonyl)piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one as a solid: 1 H NMR (400 MHz, CDCl 3 ) 9.95 (m, 1H), 8.81 (s, 2H), 7.28 (m, 2H), 7.08 (m, 2H), 4.77 (s, 1H), 4.35 (m, 1H), 3.80 (s, 1H), 3.12 (m, 4H). 2.88 (m, 1H), 2.68 (m, 1
- Step 4 The 1 ,3-dihydro-1- ⁇ 1 -[ 1 -(2-tert-butoxycarbonylamino-5-pyrimidinylcarbonyl)piperidin-4-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one was dissolved in ethyl acetate, cooled to -50°C and treated with a stream of HCl gas for 2 min. The reaction mixture was allowed to warm to room temperature and stir for several hours, and then concentrated to dryness under reduced pressure.
- Step 1 To a stirred solution of 1,3-dihydro-1- ⁇ 1-[4-oxocyclohex-1-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one (100 mg) in methanol (4 mL) at 0°C, under nitrogen, was added tert-butylamine-borane (28 mg). The reaction mixture was stirred at 0°C for 1 h, then quenched with water (2 mL) and concentrated to remove the methanol.
- the resulting oil was dissolved in ethyl acetate (50 mL) and the organic solution was washed with saturated sodium carbonate (10 mL), then water (10 mL), then brine (10 mL) and then dried over sodium sulfate.
- hydrochloride salt was precipitated from diethyl ether/chloroform:
- Step 1 To a stirred solution of 1,3-dihydro-1- ⁇ 1-[4-oxocyclohex-1-yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-one (100 mg) in dry
- CHO cells When 80- 100% confluent, CHO cells were harvested, and transferred to centrifuge tubes containing CHO buffer (20 mM HEPES at pH 7.4 containing 5mM MgCl 2 ). The cells were
- the homogenate was centrifuged at 40,000 ⁇ g for 15 minutes at 4°C in a Beckman J2-21 M centrifuge.
- membranes were resuspended in CHO buffer to a concentration of one flask harvested (75 cm 2 ) per mL of buffer, mixed well and aliquoted in cryovials ( 1mL/vial). The vials were stored at -70°C until used in the assay. The binding incubation was done in
- polypropylene macrowell tube strips in a final volume of 0.5 mL of HEPES buffer (20 mM; pH 7.4 containing 5 mM MgCl 2 ) containing 0.1 mL of cell membrane suspension, 3H-N-methylscopolamine (NEN Corporation, NET-636, 70-87 C i /mmole) at a final volume of 0.5 mL of HEPES buffer (20 mM; pH 7.4 containing 5 mM MgCl 2 ) containing 0.1 mL of cell membrane suspension, 3H-N-methylscopolamine (NEN Corporation, NET-636, 70-87 C i /mmole) at a final
- K i values were calculated using the program LIGAND.
- Compounds displayed K i values at m1 , m2 and m4 in the range of InM to 5,000 nM. All compounds described herein displayed typically greater than 300-fold less potency at the m3 receptor subtype, in the range of 300 nM to 1 14,000 nM.
- tissue segments are attached to platinum electrodes with 4-0 surgical silk and placed in a 10 mL jacketed tissue bath containing Krebs buffer at 30°C, bubbled with 5% CO 2 / 95% O 2 .
- the tissues are connected to a Statham-Gould force transducer; 0.75 gram of tension is applied and the tissues are electrically stimulated.
- EFS parameters are 0.05 Hz; 0.5 ms duration; voltage is set to 30% of 50 V at 25 ohms and increased until a supramaximal voltage is achieved.
- the contractions are recorded on a Gould strip chart recorder. The tissues are washed every 20 minutes and allowed to equilibrate.
- a concentration response curve to the selective ml receptor agonist McN-A-343 is determined. Tissues are washed every 20 minutes for 60 minutes. The vehicle or compound is added to the bath and the tissues are incubated for 30 minutes, then the McN-A-343 concentration response is repeated. EC 50 values are determined for both vehicle and tissues treated with the compound before and after treatment. Antagonist dissociation constants (K b ) are calculated by the dose-ratio method. Compounds displayed K b values at m l generally consistent with the radioligand binding assay described in Example 30 in the range of 5 to 100 nM.
- dextrose 1 1 mM warmed to 37°C.
- Each atria is attached to platinum electrodes with 4-0 surgical silk and placed in a 10 mL jacketed tissue bath containing Krebs buffer at 37°C, bubbled with 5% CO 2 / 95% O 2 .
- the tissues are connected to a Statham-Gould force transducer; 0.75 gram of tension is applied and the tissues are electrically stimulated. [EFS parameters are 3 Hz; 4 ms duration; voltage is set to 5 V.]
- the contractions are recorded on a Gould strip chart recorder.
- the tissues are washed every 20 minutes and allowed to equilibrate.
- a concentration response curve to the agonist carbachol is determined. Tissues are washed every 20 minutes for 60 minutes. The vehicle or compound is added to the bath and the tissues are incubated for 30 minutes, then the carbachol
- Antagonist dissociation constants are calculated by the dose-ratio method.
- Compounds displayed K b values at M2 generally consistent with the radioligand binding assay described in Example 30 in the range of 5 to 100 nM.
- the lumen of the remainder is flushed with oxygenated Krebs solution [NaCl, 1 18 mM; KCl, 4.7 mM; CaCl 2 , 2.5 mM: KH 2 PO 4 , 1.2 mM; MgSO 4 , 1.2 mM; NaHCO 3 , 25 mM; dextrose, 1 1 mM] warmed to 30°C.
- the ileum is cut into 2.5 cm segments and each segment is mounted on a glass pipette.
- a scalpel is used to lightly cut the surface of the tissue and a cotton swab used to tease the longitudinal muscle free from the underlying circular muscle.
- EC 50 values are determined for both vehicle and tissues treated with the compound before and after treatment.
- Antagonist dissociation constants (K b ) are calculated by the dose-ratio method.
- Compounds displayed K b values at M3 generally consistent with the radioligand binding assay described in Example 30 in the range of 3900 to 24000 nM.
- EXAMPLE 72 ml and m3 receptor antagonist activity on the human muscarinic receptors expressed in CHO cells
- Preconfluent CHO cells were labeled for 24 hours with 4 ⁇ Ci/mL of [ 3 H] myo-inositol (specific activity 15-20 Ci /mmole).
- the cells were detached from flasks using 1 mM EDTA in phosphate buffer saline, centrifuged for 5 minutes at 200x g, and resuspended in assay buffer (1 16 mM NaCl; 10 mM LiCl; 4.7 mM KCl; 1.2 mM MgSO 4 ; 2.5 mM CaCl 2 ; 1.2 mM KH 2 PO 4 ; 5 mM NaHCO 3 ; 1 1 mM dextrose, 20 mM HEPES; pH 7.4 at 37°C) to the desired volume.
- K b values were generated by performing carbachol concentration-response curves in the absence and presence of a fixed concentration of compound.
- Compounds displayed K b values at ml and m3 generally consistent with the radioligand binding assay described in Example 30 in the range of 1 to 100 nM at m 1 and 4,000 to 20,000 at m3.
- Preconfluent CHO cells were harvested using 1 mM
- Muscarinic agonist 50 microliters of carbachol; 1 micromolar final concentration
- 20 microliters of 200 ⁇ M forskolin was then added followed by 20 microliters of 200 ⁇ M forskolin and the tubes were incubated at 30°C for an additional 15 minutes.
- the reaction was stopped by placing the tubes in boiling water for 5 minutes.
- the tubes were cooled on ice and then centrifuged at 12,000 xg for 10 minutes. Fifty microliters of each supernatant was then analyzed for cAMP using a commercially available radioimmunoassay kit following the manufacturer's instructions.
- K b values were generated by performing carbachol concentration-response curves in the absence and presence of a fixed concentration of compound.
- Compounds displayed K b values at m2 generally consistent with the radioligand binding assay described in Example 30 in the range of 1 to 100 nM.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP51469196A JP2002515008A (en) | 1994-10-27 | 1995-10-24 | Muscarinic antagonist |
AU39674/95A AU701127B2 (en) | 1994-10-27 | 1995-10-24 | Muscarine antagonists |
EP95937615A EP0786997A4 (en) | 1994-10-27 | 1995-10-24 | Muscarine antagonists |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/329,757 US5574044A (en) | 1994-10-27 | 1994-10-27 | Muscarine antagonists |
US329,757 | 1994-10-27 | ||
US440,153 | 1995-05-12 | ||
US08/440,153 US5691323A (en) | 1995-05-12 | 1995-05-12 | Muscarine antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996013262A1 true WO1996013262A1 (en) | 1996-05-09 |
Family
ID=26986957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/013710 WO1996013262A1 (en) | 1994-10-27 | 1995-10-24 | Muscarine antagonists |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0786997A4 (en) |
JP (1) | JP2002515008A (en) |
AU (1) | AU701127B2 (en) |
CA (1) | CA2200468A1 (en) |
WO (1) | WO1996013262A1 (en) |
Cited By (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2751647A1 (en) * | 1996-07-25 | 1998-01-30 | Synthelabo | BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATIONS AND THEIR THERAPEUTIC APPLICATIONS |
WO1998017646A1 (en) * | 1996-10-21 | 1998-04-30 | Dr. Karl Thomae Gmbh | 1-(4-piperdinyl)-piperidinylene as aggregation inhibitor |
WO1999032479A1 (en) * | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparation and their use as muscarinic receptor (ant-)agonists |
EP0990653A4 (en) * | 1997-05-30 | 2001-04-11 | Banyu Pharma Co Ltd | 2-0XOIMIDAZOLE DERIVATIVES |
WO2001044213A1 (en) * | 1999-12-17 | 2001-06-21 | Astrazeneca Ab | New p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases |
WO2002085890A1 (en) * | 2001-04-20 | 2002-10-31 | Banyu Pharmaceutical Co., Ltd. | Benzimidazolone derivatives |
EP1221443A4 (en) * | 1999-10-13 | 2002-11-04 | Banyu Pharma Co Ltd | Substituted imidazolidinone derivatives |
JP2003513088A (en) * | 1999-10-29 | 2003-04-08 | ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and methods for their preparation |
WO2003028650A3 (en) * | 2001-10-02 | 2003-06-19 | Acadia Pharm Inc | Benzimidazolidinone derivatives as muscarinic agents |
WO2003103669A1 (en) * | 2002-04-18 | 2003-12-18 | Schering Corporation | 1-(4-piperidinyl) benzimidazolones as histamine h3 antagonists |
WO2003105781A2 (en) | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
WO2004069828A1 (en) * | 2003-02-04 | 2004-08-19 | Mitsubishi Pharma Corporation | Piperidine compound and medicinal use thereof |
WO2004089942A3 (en) * | 2001-10-02 | 2004-11-25 | Acadia Pharm Inc | Benzimidazolidinone derivatives as muscarinic agents |
US6828460B2 (en) | 1999-03-22 | 2004-12-07 | Pfizer Inc. | Resorcinol derivatives |
US6881754B2 (en) | 1999-12-17 | 2005-04-19 | Astrazeneca Ab | Adamantane derivatives |
US6951849B2 (en) | 2001-10-02 | 2005-10-04 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
EP1598339A1 (en) * | 2001-04-18 | 2005-11-23 | Euro-Celtique S.A. | 1-(4-amino-cyclohexyl)-1,3-dihydro-2h-benzimidazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain |
WO2007007890A1 (en) * | 2005-07-13 | 2007-01-18 | Banyu Pharmaceutical Co., Ltd. | N-dihydroxyalkyl-substituted 2-oxoimidazole derivative |
US7196090B2 (en) | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
WO2007036715A3 (en) * | 2005-09-30 | 2007-05-18 | Glaxo Group Ltd | Compounds which have activity at m1 receptor and their uses in medicine |
WO2007107566A1 (en) * | 2006-03-22 | 2007-09-27 | Glaxo Group Limited | Benzimidazoles which have activity at m1 receptor and their uses in medicine |
WO2007107565A1 (en) * | 2006-03-22 | 2007-09-27 | Glaxo Group Limited | Benzimidazoles which have activity at m1 receptor and their uses in medicine |
WO2007107567A1 (en) * | 2006-03-22 | 2007-09-27 | Glaxo Group Limited | Benzimidazoles which have activity at m1 receptor and their uses in medicine |
WO2007142585A1 (en) * | 2006-06-09 | 2007-12-13 | Astrazeneca Ab | Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia |
WO2007142583A1 (en) * | 2006-06-09 | 2007-12-13 | Astrazeneca Ab | Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia. |
WO2008119713A1 (en) * | 2007-03-29 | 2008-10-09 | Glaxo Group Limited | 1- (1-cyclohexyl-4-piperidinyl) -1, 3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine |
WO2008119715A1 (en) * | 2007-03-29 | 2008-10-09 | Glaxo Group Limited | 1- (1-cyclohexyl-4-piperidinyl) -1, 3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine |
WO2008119720A1 (en) * | 2007-03-29 | 2008-10-09 | Glaxo Group Limited | 1-(1-cyclobutyl-4-piperidinyl)-1,3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine |
WO2008119719A1 (en) * | 2007-03-29 | 2008-10-09 | Glaxo Group Limited | 1- (1-cyclohexyl-4-piperidinyl) -1, 3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine |
WO2008119718A1 (en) * | 2007-03-29 | 2008-10-09 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
WO2008119717A1 (en) * | 2007-03-29 | 2008-10-09 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
WO2008119721A1 (en) * | 2007-03-29 | 2008-10-09 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
US7501425B1 (en) | 1998-05-26 | 2009-03-10 | Warner Lambert Company | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation |
WO2009124883A1 (en) * | 2008-04-09 | 2009-10-15 | H. Lundbeck A/S | Novel 1,3-dihydro-benzoimidazol-2-ones as m1 agonists |
WO2009136850A1 (en) * | 2008-05-05 | 2009-11-12 | Astrazeneca Ab | Muscarinic receptor agonits useful in the treatment of pain, alzheimer's disease and schizophrenia |
US7745623B2 (en) | 2004-05-21 | 2010-06-29 | Takeda Pharmaceutical Company Limited | Cyclic amide derivative, and its production and use |
US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
US8288412B2 (en) | 2005-09-30 | 2012-10-16 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
US8288413B2 (en) | 2005-09-30 | 2012-10-16 | Glaxo Group Limited | Benzimidazolones which have activity at M1 receptor |
US8344000B2 (en) | 2007-09-20 | 2013-01-01 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
WO2013130890A1 (en) * | 2012-02-29 | 2013-09-06 | Amgen Inc. | Heterobicyclic compounds and their use as phosphodiesterase inhibitors |
WO2014122474A1 (en) | 2013-02-07 | 2014-08-14 | Takeda Pharmaceutical Company Limited | Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists |
WO2017058805A1 (en) * | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
US9840516B2 (en) | 2013-10-10 | 2017-12-12 | Araxes Pharma Llc | Substituted quinazolines as inhibitors of KRAS G12C |
US9862701B2 (en) | 2014-09-25 | 2018-01-09 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US9926267B2 (en) | 2013-03-15 | 2018-03-27 | Araxes Pharma Llc | Covalent inhibitors of K-Ras G12C |
US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
WO2018174149A1 (en) * | 2017-03-23 | 2018-09-27 | Singapore Health Services Pte Ltd | Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient |
WO2018174145A1 (en) * | 2017-03-23 | 2018-09-27 | Singapore Health Services Pte Ltd | Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising umeclidinium as active ingredient |
US10111874B2 (en) | 2014-09-18 | 2018-10-30 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
US10246424B2 (en) | 2015-04-10 | 2019-04-02 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
US10259787B2 (en) | 2016-10-14 | 2019-04-16 | Heptares Therapeutics Limited | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists |
US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
CN109996792A (en) * | 2016-10-14 | 2019-07-09 | 赫普泰雅治疗有限公司 | With the active heterocyclic compound in treatment CNS disease and pain as the regulator of muscarinic M 1 and/or M4 receptor |
US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
US10414757B2 (en) | 2015-11-16 | 2019-09-17 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
US10428064B2 (en) | 2015-04-15 | 2019-10-01 | Araxes Pharma Llc | Fused-tricyclic inhibitors of KRAS and methods of use thereof |
US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10736897B2 (en) | 2017-05-25 | 2020-08-11 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
US10745385B2 (en) | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US11059819B2 (en) | 2017-01-26 | 2021-07-13 | Janssen Biotech, Inc. | Fused hetero-hetero bicyclic compounds and methods of use thereof |
US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
US11773090B2 (en) | 2018-06-22 | 2023-10-03 | Heptares Therapeutics Limited | Pharmaceutical compounds |
US11793817B2 (en) | 2011-11-18 | 2023-10-24 | Heptares Therapeutics Limited | Muscarinic M1 receptor agonists |
US11945801B2 (en) | 2018-12-07 | 2024-04-02 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists |
US11999745B2 (en) | 2020-12-18 | 2024-06-04 | Heptares Therapeutics Limited | Pharmaceutical compounds |
US12024499B2 (en) | 2015-08-03 | 2024-07-02 | Heptares Therapeutics Limited | Muscarinic agonists |
US12134620B2 (en) | 2018-08-01 | 2024-11-05 | Araxes Pharma Llc | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer |
US12202843B2 (en) | 2014-03-19 | 2025-01-21 | Nxera Pharma Uk Limited | Muscarinic receptor agonists |
US12215099B2 (en) | 2018-12-07 | 2025-02-04 | Nxera Pharma Uk Limited | Quinolinone and benzoxazine derivatives as muscarinic M1 and/or M4 receptor agonists |
US12291512B2 (en) | 2015-11-02 | 2025-05-06 | Nxera Pharma Uk Limited | Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor |
EP4392418A4 (en) * | 2021-08-24 | 2025-06-18 | The Johns Hopkins University | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH PROTEOTOXICITY |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ577948A (en) * | 2006-12-26 | 2012-03-30 | Quadra Logic Tech Inc | Drug delivery implants for inhibition of optical defects |
US8299257B2 (en) * | 2007-09-20 | 2012-10-30 | Glaxo Group Limited | Compounds which have activity at M1receptor and their uses in medicine |
EP2194982A1 (en) * | 2007-09-20 | 2010-06-16 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
WO2015138700A1 (en) * | 2014-03-13 | 2015-09-17 | Bodor Laboratories, Inc. | Use of selected anticholinergic zwitterions |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4066772A (en) * | 1975-07-21 | 1978-01-03 | Janssen Pharmaceutica N.V. | 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds |
US5128327A (en) * | 1991-03-25 | 1992-07-07 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle |
US5284843A (en) * | 1988-06-03 | 1994-02-08 | Trustees Of The University Of Penna. | Pharmacological treatment of ocular development |
US5322847A (en) * | 1992-11-05 | 1994-06-21 | Pfizer Inc. | Azabenzimidazoles in the treatment of asthma, arthritis and related diseases |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4329353A (en) * | 1980-10-22 | 1982-05-11 | Janssen Pharmaceutica, N.V. | 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof |
-
1995
- 1995-10-24 JP JP51469196A patent/JP2002515008A/en active Pending
- 1995-10-24 AU AU39674/95A patent/AU701127B2/en not_active Ceased
- 1995-10-24 EP EP95937615A patent/EP0786997A4/en not_active Withdrawn
- 1995-10-24 WO PCT/US1995/013710 patent/WO1996013262A1/en not_active Application Discontinuation
- 1995-10-24 CA CA002200468A patent/CA2200468A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4066772A (en) * | 1975-07-21 | 1978-01-03 | Janssen Pharmaceutica N.V. | 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds |
US5284843A (en) * | 1988-06-03 | 1994-02-08 | Trustees Of The University Of Penna. | Pharmacological treatment of ocular development |
US5128327A (en) * | 1991-03-25 | 1992-07-07 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle |
US5322847A (en) * | 1992-11-05 | 1994-06-21 | Pfizer Inc. | Azabenzimidazoles in the treatment of asthma, arthritis and related diseases |
Non-Patent Citations (1)
Title |
---|
See also references of EP0786997A4 * |
Cited By (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998004546A1 (en) * | 1996-07-25 | 1998-02-05 | Synthelabo | Benzimidazole derivatives, preparation thereof, and therapeutical uses thereof |
FR2751647A1 (en) * | 1996-07-25 | 1998-01-30 | Synthelabo | BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATIONS AND THEIR THERAPEUTIC APPLICATIONS |
WO1998017646A1 (en) * | 1996-10-21 | 1998-04-30 | Dr. Karl Thomae Gmbh | 1-(4-piperdinyl)-piperidinylene as aggregation inhibitor |
EP0990653A4 (en) * | 1997-05-30 | 2001-04-11 | Banyu Pharma Co Ltd | 2-0XOIMIDAZOLE DERIVATIVES |
US6258825B1 (en) | 1997-05-30 | 2001-07-10 | Banyu Pharmaceutical Co., Ltd. | 2-oxoimidazole derivatives |
WO1999032479A1 (en) * | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparation and their use as muscarinic receptor (ant-)agonists |
US7501425B1 (en) | 1998-05-26 | 2009-03-10 | Warner Lambert Company | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation |
US6933319B2 (en) | 1999-03-22 | 2005-08-23 | Pfizer Inc. | Resorcinol derivatives |
US6828460B2 (en) | 1999-03-22 | 2004-12-07 | Pfizer Inc. | Resorcinol derivatives |
EP1221443A4 (en) * | 1999-10-13 | 2002-11-04 | Banyu Pharma Co Ltd | Substituted imidazolidinone derivatives |
US6699880B1 (en) | 1999-10-13 | 2004-03-02 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazolidinone derivatives |
JP2003513088A (en) * | 1999-10-29 | 2003-04-08 | ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and methods for their preparation |
WO2001044213A1 (en) * | 1999-12-17 | 2001-06-21 | Astrazeneca Ab | New p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases |
CN1304382C (en) * | 1999-12-17 | 2007-03-14 | 阿斯特拉曾尼卡有限公司 | Novel P2X7 receptor antagonists for the treatment of inflammatory, immune or cardiovascular diseases |
US7297818B2 (en) | 1999-12-17 | 2007-11-20 | Astrazeneca Ab | Adamantane derivatives |
US6812226B2 (en) | 1999-12-17 | 2004-11-02 | Astrazeneca Ab | P2X7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular disease |
US6881754B2 (en) | 1999-12-17 | 2005-04-19 | Astrazeneca Ab | Adamantane derivatives |
US7132457B2 (en) | 1999-12-17 | 2006-11-07 | Astrazeneca Ab | Adamantane derivatives |
EP1598339A1 (en) * | 2001-04-18 | 2005-11-23 | Euro-Celtique S.A. | 1-(4-amino-cyclohexyl)-1,3-dihydro-2h-benzimidazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain |
US7164024B2 (en) | 2001-04-20 | 2007-01-16 | Banyu Pharmaceutical Co., Ltd. | Benzimidazolone derivatives |
WO2002085890A1 (en) * | 2001-04-20 | 2002-10-31 | Banyu Pharmaceutical Co., Ltd. | Benzimidazolone derivatives |
WO2004089942A3 (en) * | 2001-10-02 | 2004-11-25 | Acadia Pharm Inc | Benzimidazolidinone derivatives as muscarinic agents |
US7300928B2 (en) | 2001-10-02 | 2007-11-27 | Acadia Pharmaceuticals, Inc. | Benzimidazolidinone derivatives as muscarinic agents |
US6951849B2 (en) | 2001-10-02 | 2005-10-04 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
US7087593B2 (en) | 2001-10-02 | 2006-08-08 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
US7273857B2 (en) | 2001-10-02 | 2007-09-25 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
KR100809569B1 (en) * | 2001-10-02 | 2008-03-04 | 아카디아 파마슈티칼스 인코포레이티드 | Benzimidazolidinone derivatives as muscarinic agents |
US7291611B2 (en) | 2001-10-02 | 2007-11-06 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
WO2003028650A3 (en) * | 2001-10-02 | 2003-06-19 | Acadia Pharm Inc | Benzimidazolidinone derivatives as muscarinic agents |
JP2006206603A (en) * | 2002-04-18 | 2006-08-10 | Schering Plough Corp | 1-(4-piperidinyl)benzimidazolone as histamine h3 antagonist |
JP2005529161A (en) * | 2002-04-18 | 2005-09-29 | シェーリング コーポレイション | 1- (4-Piperidinyl) benzimidazolone as a histamine H3 antagonist |
WO2003103669A1 (en) * | 2002-04-18 | 2003-12-18 | Schering Corporation | 1-(4-piperidinyl) benzimidazolones as histamine h3 antagonists |
US7220735B2 (en) | 2002-04-18 | 2007-05-22 | Schering Corporation | Benzimidazolone histamine H3 antagonists |
WO2003105781A2 (en) | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
JP2005532361A (en) * | 2002-06-17 | 2005-10-27 | メルク エンド カムパニー インコーポレーテッド | Ophthalmic composition for the treatment of ocular hypertension |
US7279490B2 (en) | 2002-06-17 | 2007-10-09 | Merck & Co, Inc. | Ophthalmic compositions for treating ocular hypertension |
US7196090B2 (en) | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
WO2004069828A1 (en) * | 2003-02-04 | 2004-08-19 | Mitsubishi Pharma Corporation | Piperidine compound and medicinal use thereof |
US8697865B2 (en) | 2004-05-21 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Cyclic amide derivative, and its production and use |
US7745623B2 (en) | 2004-05-21 | 2010-06-29 | Takeda Pharmaceutical Company Limited | Cyclic amide derivative, and its production and use |
WO2007007890A1 (en) * | 2005-07-13 | 2007-01-18 | Banyu Pharmaceutical Co., Ltd. | N-dihydroxyalkyl-substituted 2-oxoimidazole derivative |
AU2006296369B2 (en) * | 2005-09-30 | 2012-12-20 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
KR101374458B1 (en) * | 2005-09-30 | 2014-03-17 | 글락소 그룹 리미티드 | Compounds which have activity at m1 receptor and their uses in medicine |
US8481566B2 (en) | 2005-09-30 | 2013-07-09 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
US8288413B2 (en) | 2005-09-30 | 2012-10-16 | Glaxo Group Limited | Benzimidazolones which have activity at M1 receptor |
US8288412B2 (en) | 2005-09-30 | 2012-10-16 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
US8283364B2 (en) | 2005-09-30 | 2012-10-09 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
EA016286B1 (en) * | 2005-09-30 | 2012-03-30 | Глэксо Груп Лимитед | Compounds which have activity at mreceptor and their uses in medicine |
WO2007036715A3 (en) * | 2005-09-30 | 2007-05-18 | Glaxo Group Ltd | Compounds which have activity at m1 receptor and their uses in medicine |
WO2007107566A1 (en) * | 2006-03-22 | 2007-09-27 | Glaxo Group Limited | Benzimidazoles which have activity at m1 receptor and their uses in medicine |
WO2007107567A1 (en) * | 2006-03-22 | 2007-09-27 | Glaxo Group Limited | Benzimidazoles which have activity at m1 receptor and their uses in medicine |
US20120316202A1 (en) * | 2006-03-22 | 2012-12-13 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
US20120309789A1 (en) * | 2006-03-22 | 2012-12-06 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
WO2007107565A1 (en) * | 2006-03-22 | 2007-09-27 | Glaxo Group Limited | Benzimidazoles which have activity at m1 receptor and their uses in medicine |
CN101448495B (en) * | 2006-03-22 | 2013-05-08 | 葛兰素集团有限公司 | Benzimidazole compounds active on M1 receptors and their application in medicine |
US7956069B2 (en) | 2006-06-09 | 2011-06-07 | Astrazeneca Ab | Compounds |
WO2007142585A1 (en) * | 2006-06-09 | 2007-12-13 | Astrazeneca Ab | Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia |
WO2007142583A1 (en) * | 2006-06-09 | 2007-12-13 | Astrazeneca Ab | Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia. |
WO2008119718A1 (en) * | 2007-03-29 | 2008-10-09 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
WO2008119719A1 (en) * | 2007-03-29 | 2008-10-09 | Glaxo Group Limited | 1- (1-cyclohexyl-4-piperidinyl) -1, 3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine |
WO2008119720A1 (en) * | 2007-03-29 | 2008-10-09 | Glaxo Group Limited | 1-(1-cyclobutyl-4-piperidinyl)-1,3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine |
WO2008119715A1 (en) * | 2007-03-29 | 2008-10-09 | Glaxo Group Limited | 1- (1-cyclohexyl-4-piperidinyl) -1, 3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine |
WO2008119713A1 (en) * | 2007-03-29 | 2008-10-09 | Glaxo Group Limited | 1- (1-cyclohexyl-4-piperidinyl) -1, 3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine |
WO2008119721A1 (en) * | 2007-03-29 | 2008-10-09 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
WO2008119717A1 (en) * | 2007-03-29 | 2008-10-09 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
US8344000B2 (en) | 2007-09-20 | 2013-01-01 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
WO2009124883A1 (en) * | 2008-04-09 | 2009-10-15 | H. Lundbeck A/S | Novel 1,3-dihydro-benzoimidazol-2-ones as m1 agonists |
CN102083812A (en) * | 2008-05-05 | 2011-06-01 | 阿斯利康(瑞典)有限公司 | Muscarinic receptor agonits useful in the treatment of pain, alzheimer's disease and schizophrenia |
WO2009136850A1 (en) * | 2008-05-05 | 2009-11-12 | Astrazeneca Ab | Muscarinic receptor agonits useful in the treatment of pain, alzheimer's disease and schizophrenia |
US11793817B2 (en) | 2011-11-18 | 2023-10-24 | Heptares Therapeutics Limited | Muscarinic M1 receptor agonists |
US9174992B2 (en) | 2012-02-29 | 2015-11-03 | Amgen Inc. | Heterobicyclic compounds |
WO2013130890A1 (en) * | 2012-02-29 | 2013-09-06 | Amgen Inc. | Heterobicyclic compounds and their use as phosphodiesterase inhibitors |
WO2014122474A1 (en) | 2013-02-07 | 2014-08-14 | Takeda Pharmaceutical Company Limited | Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists |
US9593106B2 (en) | 2013-02-07 | 2017-03-14 | Heptares Therapeutics Limited | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists |
US10030012B2 (en) | 2013-02-07 | 2018-07-24 | Heptares Therapeutics Limited | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists |
US10919850B2 (en) | 2013-03-15 | 2021-02-16 | Araxes Pharma Llc | Covalent inhibitors of KRas G12C |
US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
US10273207B2 (en) | 2013-03-15 | 2019-04-30 | Araxes Pharma Llc | Covalent inhibitors of kras G12C |
US9926267B2 (en) | 2013-03-15 | 2018-03-27 | Araxes Pharma Llc | Covalent inhibitors of K-Ras G12C |
USRE50527E1 (en) | 2013-03-15 | 2025-08-12 | Araxes Pharma Llc | Covalent inhibitors of KRAS G12C |
US9840516B2 (en) | 2013-10-10 | 2017-12-12 | Araxes Pharma Llc | Substituted quinazolines as inhibitors of KRAS G12C |
US10370386B2 (en) | 2013-10-10 | 2019-08-06 | Araxes Pharma Llc | Substituted quinolines as inhibitors of KRAS G12C |
US10927125B2 (en) | 2013-10-10 | 2021-02-23 | Araxes Pharma Llc | Substituted cinnolines as inhibitors of KRAS G12C |
US12234244B2 (en) | 2013-10-10 | 2025-02-25 | Araxes Pharma Llc | Substituted piperazines as inhibitors of KRAS G12C |
US11878985B2 (en) | 2013-10-10 | 2024-01-23 | Araxes Pharma Llc | Substituted quinazolines as inhibitors of KRAS G12C |
US12202843B2 (en) | 2014-03-19 | 2025-01-21 | Nxera Pharma Uk Limited | Muscarinic receptor agonists |
US10111874B2 (en) | 2014-09-18 | 2018-10-30 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
US9862701B2 (en) | 2014-09-25 | 2018-01-09 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
USRE50490E1 (en) | 2015-04-10 | 2025-07-15 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
US10246424B2 (en) | 2015-04-10 | 2019-04-02 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
US10829458B2 (en) | 2015-04-10 | 2020-11-10 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
US10428064B2 (en) | 2015-04-15 | 2019-10-01 | Araxes Pharma Llc | Fused-tricyclic inhibitors of KRAS and methods of use thereof |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
US10351550B2 (en) | 2015-07-22 | 2019-07-16 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
US12024499B2 (en) | 2015-08-03 | 2024-07-02 | Heptares Therapeutics Limited | Muscarinic agonists |
US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017058805A1 (en) * | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US12291512B2 (en) | 2015-11-02 | 2025-05-06 | Nxera Pharma Uk Limited | Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor |
US10414757B2 (en) | 2015-11-16 | 2019-09-17 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
US11021470B2 (en) | 2015-11-16 | 2021-06-01 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10723738B2 (en) | 2016-09-29 | 2020-07-28 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
US10759751B2 (en) | 2016-10-14 | 2020-09-01 | Heptares Therapeutics Limited | Substituted spirocyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists |
US11014880B2 (en) | 2016-10-14 | 2021-05-25 | Heptares Therapeutics Limited | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists |
US11834407B2 (en) | 2016-10-14 | 2023-12-05 | Heptares Therapeutics Limited | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists |
US10259787B2 (en) | 2016-10-14 | 2019-04-16 | Heptares Therapeutics Limited | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists |
CN109996792A (en) * | 2016-10-14 | 2019-07-09 | 赫普泰雅治疗有限公司 | With the active heterocyclic compound in treatment CNS disease and pain as the regulator of muscarinic M 1 and/or M4 receptor |
US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
US11059819B2 (en) | 2017-01-26 | 2021-07-13 | Janssen Biotech, Inc. | Fused hetero-hetero bicyclic compounds and methods of use thereof |
WO2018174145A1 (en) * | 2017-03-23 | 2018-09-27 | Singapore Health Services Pte Ltd | Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising umeclidinium as active ingredient |
US11642350B2 (en) | 2017-03-23 | 2023-05-09 | Singapore Health Services Pte Ltd | Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient |
JP7016880B2 (en) | 2017-03-23 | 2022-02-07 | シンガポール ヘルス サービシーズ ピーティーイー リミテッド | Myopia prophylaxis, myopia treatment and / or myopia progression inhibitor containing tiotropium as an active ingredient |
JP2020514347A (en) * | 2017-03-23 | 2020-05-21 | シンガポール ヘルス サービシーズ ピーティーイー リミテッド | Myopia prevention, myopia treatment and / or myopia progression inhibitor containing tiotropium as an active ingredient |
WO2018174149A1 (en) * | 2017-03-23 | 2018-09-27 | Singapore Health Services Pte Ltd | Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient |
US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
US11377441B2 (en) | 2017-05-25 | 2022-07-05 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
US10736897B2 (en) | 2017-05-25 | 2020-08-11 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
US10745385B2 (en) | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
US11773090B2 (en) | 2018-06-22 | 2023-10-03 | Heptares Therapeutics Limited | Pharmaceutical compounds |
US12134620B2 (en) | 2018-08-01 | 2024-11-05 | Araxes Pharma Llc | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer |
US11945801B2 (en) | 2018-12-07 | 2024-04-02 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists |
US12215099B2 (en) | 2018-12-07 | 2025-02-04 | Nxera Pharma Uk Limited | Quinolinone and benzoxazine derivatives as muscarinic M1 and/or M4 receptor agonists |
US11999745B2 (en) | 2020-12-18 | 2024-06-04 | Heptares Therapeutics Limited | Pharmaceutical compounds |
EP4392418A4 (en) * | 2021-08-24 | 2025-06-18 | The Johns Hopkins University | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH PROTEOTOXICITY |
Also Published As
Publication number | Publication date |
---|---|
EP0786997A4 (en) | 1998-03-11 |
AU701127B2 (en) | 1999-01-21 |
JP2002515008A (en) | 2002-05-21 |
CA2200468A1 (en) | 1996-05-09 |
AU3967495A (en) | 1996-05-23 |
EP0786997A1 (en) | 1997-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU701127B2 (en) | Muscarine antagonists | |
US5574044A (en) | Muscarine antagonists | |
US5691323A (en) | Muscarine antagonists | |
JP5335426B2 (en) | Diarylamine-containing compounds and compositions and their use as modulators of C-KIT receptors | |
AU2019294414B2 (en) | Compounds | |
DE69331329T2 (en) | HETEROCYCLIC ETHER DERIVATIVES FOR STRENGTHENING THE COGNITIVE FUNCTIONS | |
US5422351A (en) | Bis-benzo or benzopyrido cyclohepta piperidene, piperidylidene and piperazine compounds, compositions and methods of use | |
US5756508A (en) | Muscarine antagonists | |
US20070027118A1 (en) | Novel compounds of amino sulfonyl derivatives | |
AU2005208887B2 (en) | Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity | |
AU2011291110B2 (en) | Pyrimidine derivatives as FAK inhibitors | |
CA2315117C (en) | Heterocyclic ether and thioether compounds useful in controlling chemical synaptic transmission | |
WO2007018998A2 (en) | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | |
PL192397B1 (en) | Derivatives of piperidine substituted at their position 4 with 1,2-substituted 1-piperidinyl radical a antagonists of tachykinin receptor | |
CA2810696A1 (en) | Pyrazoloquinoline compound | |
CA2607874A1 (en) | Quinoline derivatives as neurokinin receptor antagonists | |
JP2012532916A (en) | Spiroamino compounds especially suitable for the treatment of sleep disorders and drug addiction | |
WO1997016192A1 (en) | Muscarine antagonists | |
CA3073333A1 (en) | Bezimidazole derivatives as adenosine receptor antagonists | |
CA3127284A1 (en) | Thiazolopyridine derivatives as adenosine receptor antagonists | |
WO1997016187A1 (en) | Muscarine antagonists | |
US5852016A (en) | Quinoxaline derivatives useful in therapy | |
JP2918508B2 (en) | Azetidines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA US US UZ |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2200468 Country of ref document: CA Ref country code: CA Ref document number: 2200468 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995937615 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995937615 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995937615 Country of ref document: EP |